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ABBREVIATIONS 
 
AGU   aspartylglucosaminuria 
ALMS   Alström syndrome 
ALMS1   gene for Alström syndrome 
APECED  autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
AP3   adaptor-related protein complex 3  
AP3B1, AP3B1  gene for adaptor-related protein complex b subunit, protein encoded by AP3B1  
AS   Angelman syndrome 
BAC   bacterial artificial chromosome 
bp   base pair 
BLAST   basic local alignment search tool 
blastx   translated query homology search against protein database  
BBS  Bardet-Biedl syndrome 
cDNA   complementary deoxyribonucleic acid 
CEPH   Centre dÉtudes du Polymorphisme Humain 
chorein   protein for choreoacanthocytosis 
CHAC   gene for choreoacanthocytosis 
cM   centiMorgan (unit for one recombinational event in 100 meioses) 
COH1, COH1  gene for Cohen syndrome, protein encoded by COH1 
CNS   central nervous system 
COP1   coatomer 
COX6C   cytochrome c oxidase subunit VIc gene 
CpG   dinucleotides CG linked by phosphate (p) 
cR   centiRay 
db   database 
DGGE   denaturing gradient gel electrophoresis 
DHPLC   denaturing high-performance liquid chromatography 
DNA   deoxyribonucleic acid 
DORFIN  gene for human double ring finger protein 
EBI   European Bioinformatics Institute 
ELA2   gene for elastase 2 
ELK1   member of ets oncogene family 
EMBL   European Molecular Biology Laboratory 
ELN   elastin gene 
ER   endoplasmic reticulum 
EST   expressed sequence tag 
                                                                                                                   ABBREVIATIONS                                         8
ETS   ETS oncogene 
ETS1P54  member of ets protein family 
FASTA   fast sequence comparison algorithm 
GC-rich   guanosine cytosine rich 
GOA   gene ontology annotation 
HPS2   Hermansky Pudlak syndrome type 2 
IQ   intelligence quotient 
kb   kilobase (unit for 1000 nucleotides) 
LCR   ligation chain reaction 
LD   linkage disequilibrium 
LIMK1    gene for LIM domain kinase 1 
lod score  logarithm of odds value 
Mb   megabase pairs 
MRI   magnetic resonance imagining 
mRNA   messenger ribonucleic acid 
MTN   multible tissue northern blot 
NCBI   The National Center for Biotechnology Information 
NIH   National Institutes of Health 
NMD   nonsense-mediated mRNA decay 
NRF2   nuclear respiratory factor 2 protein 
OLA   oligonucleotide ligation assay 
OMIM   Online Mendelian Inheritance in Man 
OSR2   odd-skipped-related 2A gene 
PAC   P1-derived artificial chromosome 
PCR   polymerase chain reaction 
POLR2K  polymerase (RNA) II (DNA directed) polypeptide K gene 
PSI-BLAST  position-specific iterated BLAST 
PTS2   peroxisomal targeting signal 2 
PWS   Prader-Willi syndrome 
q   long arm of chromosome 
RFC2   gene for replication factor c, subunit 2 
RH   radiation hybrid 
RNA   ribonucleic acid 
RP   retinitis pigmentosa 
RT-PCR   reverse transcriptase polymerase chain reaction 
SCOP   structural classification of proteins 
SNP   single nucleotide polymorphism 
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SPAG1   gene for human sperm associated antigen 1 
SSCP   single-stranded conformational polymorphism 
SSRD   simple sequence repeats database 
Start-p value  predicted probability for the CpG Island to locate over the transcription start site  
STK3   gene for serine/threonine kinase 3 
STS   sequence-tagged site 
tblastn   protein query homology search against translated database  
TF   transcription factor 
3D-PSSM  three-dimensional position-specific scoring matrix 
TIGR   The Institute for Genomic Research 
TM   transmembrane 
UCSC   University of California Santa Cruz 
UTR   untranslated region 
VEP   visual evoked potential 
VNTR   variable number of tandem repeats 
Vps   vacuolar protein sorting associated protein 
Vps13, Vps13  gene for S. cerevisiae vacuolar protein sorting associated protein 13 
(yeast homolog for human COH1 gene), protein encoded by Vps13 
VPS13C, VPS13D human proteins belonging to VPS13 family  
WBS   Williams-Beuren syndrome 
YAC   yeast artificial chromosome 
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MEDICAL TERM GLOSSARY 
 
Acanthocytosis a disorder characterized by abnormal red blood cells with multiple thorny projections or 
spicules 
Alexithymia inability to identify own and others feelings and thus inability to communicate about 
them   
Ataxia incoordination and unsteadiness due to the brain’s failure to regulate the body’s posture and 
regulate the strength and direction of limb movements 
Cataract disease causing opacity in eye lens 
Chorea ceaseless rapid complex body movements that look well coordinated and purposeful but are, in 
fact, involuntary 
Chorioretinal dystrophy degeneration of choroideal and retinal layers that line the back of the 
eye 
Choroidea vascular layer underlying retina that lines the back of the eye 
Congenital malformation a physical defect in a newborn not defined to be either genetic or non- 
genetic by origin 
Corpus callosum the area of the brain which connects two large brain halves 
Craniofacial related to skull and face 
Cyclic neutropenia cyclic low number of neutrophils varying in severity week to week, month to 
month, and possibly follows biorhythms 
Dysmorphic feature a body characteristic that is abnormally formed 
Granulocyte a type of white blood cell filled with microscopic granules 
Granulocytopenia decrease in the number of granulocytes below normal values 
Heterogeneous disorder inherited disorder that has variable inheritance pattern or can be caused by 
several genes 
Hypogenitalism underdevelopment of the gonads 
Hypotonia decreased tone of skeletal muscles 
Intermittent neutropenia occasionally occurring low number of neutrophils 
Joint laxity hyperextensibility of the joint 
Kyphosis outward curvature of the spine, causing a humped back 
Leukopenia decrease of the number of white blood cells below normal values 
Lymphocytosis increase above normal values of lymphocytes 
Mandible the bone of the lower jaw 
Mental retardation limitations in mental functioning and in skills such as communicating, taking care of 
oneself, and social skills 
Mental deficiency synonym for mental retardation 
Microcephaly head circumference that is more than 2 standard deviations below the normal mean for age, 
sex, race, and gestation 
Myopia nearsightedness, the ability to see close objects more clearly than distant objects 
Neutrophil a subtype of white blood cell (specifically a form of granulocyte) filled with neutrally staining 
granules 
Neutropenia decrease of the number of neutrophils below normal values 
Nystagmus rapid rhythmic repetitious involuntary eye movements 
Phenotype the appearance of an individual, which results from the interaction of the person’s genetic 
makeup and his or her environment 
Pigmentary retinopathy disease that causes accumulation of the pigment granules in retina 
Philtrum the area from below the nose to the upper lip 
Polydactyli increased number of digits 
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Pulmonary arterial stenosis narrowing of the pulmonary artery above pulmonic valve, which impedes 
the flow of blood from the right ventricle into the lungs 
Retina light-sensitive nerve layer that lines the back of the eye 
Retinitis pigmentosa any one of a large group of inherited disorders in which there are abnormalities of 
the photoreceptors (the rods and cones) in the retina, which leads to progressive visual loss 
Retinochoroidal dystrophy synonym for chorioretinal dystrophy 
Retinopathy any disease of the retina 
Strabismus a condition in which the visual axes of the eyes are not parallel and the eyes appear to be 
looking in different directions 
Supravalvular aortic stenosis narrowing of the aorta above aortic valve, which impedes the flow of 
blood from the left ventricle into the aorta and the arteries of the body 
Synophrys eyebrows meet at midline 
Tapering fingers narrow fingers 
Triallelic inheritance inherited disorder in which mutations in three genes determine phenotype 
 
The modifications for definitions at URL: http://www.medterms.com/script/main/hp.asp 
were used as a basis in the creation of this glossary for medical terms.  
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ABSTRACT 
 
Cohen syndrome is an autosomal recessively inherited disorder with a broad spectrum of 
disease manifestations. Essential features for Cohen syndrome diagnosis include non-
progressive psychomotor retardation, motor clumsiness and microcephaly, typical facial 
features, childhood hypotonia and hyperextensibility of the joints, ophthalmologic findings 
of retinochoroidal dystrophy and myopia in patients over five years of age, and 
granulocytopenia. As a result of published cases with a wide variety of clinical 
manifestations, a vivid debate over the diagnostic criteria of Cohen syndrome has been 
ongoing. Cohen syndrome is one of the diseases of the `Finnish disease heritage´. The 
incidence of Cohen syndrome is higher in the Finnish population£thirty-four patients with 
Cohen syndrome have been diagnosed in Finland, and over 100 Cohen syndrome case 
reports have been published worldwide. The mutation causing Cohen syndrome has been 
enriched in Finland, due to a demographic expansion of the Finnish population followed by 
restrictions of gene flow in genetic isolates, founder effects, genetic bottlenecks, and 
chance (genetic drift). 
The main objectives of this study were to identify the gene underlying Cohen 
syndrome by a positional cloning approach, and to determine Cohen syndrome-associated 
mutations. Identification of the gene defect underlying Cohen syndrome further allowed 
determination of phenotype-genotype correlations and the definition of diagnostic criteria.  
Moreover, it laid the basis for in silico-based COH1 protein characterization. The present 
study was based on the assignment of the COH1 gene to a 10 cM interval on chromosome 
8q22.2-q22.3 by linkage analysis. The observation of linkage disequilibrium and conserved 
haplotypes in 75% of Finnish Cohen syndrome chromosomes allowed us to pinpoint the 
localization of the COH1 gene, and limited the number of positional candidate genes 
subjected to mutation analysis. In a novel transcript, identified and assembled from the 
critical region, a two base pair deletion was identified in Finnish Cohen syndrome patients 
bearing the founder haplotype. Mutation analysis in Cohen syndrome patients revealed 31 
additional COH1 mutations. Lack of mutations in “Cohen-like” patients, in which the 
clinical features did not fulfill previously established diagnostic criteria, allowed molecular 
distinction between “true” Cohen syndrome and “Cohen-like” syndromes. 
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The full-length 14,093 bp COH1 transcript was identified and assembled by in 
silico-based methods, and was verified by reverse transcriptase PCR (RT-PCR). The COH1 
gene is composed of at least 62 exons over ~864 kb of genomic DNA. Several alternatively 
spliced forms of COH1 were observed. The 14,093 bp transcript is predicted to encode a 
4,022 amino acid protein based on modelling with predicted transmembrane and other 
domains. Protein alignment against a domain family database indicated amino acid 
similarity with the S. cerevisiae Vps13 protein. This predicts that the COH1 protein has a 
function in the control of protein sorting. 
The results presented in this thesis allow molecular confirmation of the clinical 
diagnosis of Cohen syndrome and confirm the previously established diagnostic criteria. 
Moreover, the results show that Cohen and “ Cohen-like”  syndromes are clinically and 
genetically distinct disorders. This work is the basis for further characterization of the 
COH1 protein and the molecular pathogenesis of Cohen syndrome. 
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INTRODUCTION 
 
The human genome project began in 1990 with the aim to determine the entire 3,000 Mb 
human genome sequence. During this process the genome database information has grown 
exponentially, and the data submitted by the academic project has been freely available to 
the research community (Lander et al., 2001). Parallel to the academic genomic sequencing 
project, expressed sequence tagged (EST) databases, largely contributed by the commercial 
sequencing project of Celera (Venter et al., 2001), have evolved rapidly, and today contain 
over five million entries for sequence tagged sites (STSs) for human genes and 20 million 
sequences overall (http://www.ncbi.nlm.nih.gov/dbEST/dbEST_summary.html). This 
information has been utilized in compiling the 15,628 human full-length cDNAs reported in 
March, 2004 (http://mgc.nci.nih.gov/). This is about half of the expected total of 28,000-
34,000 genes in humans (Crollius et al., 2002), a number derived from knowledge of other 
species’ genomic sequence and gene sequence frequencies. However, the number of genes 
does not include functional units such as regulatory regions. Alongside these, the diversity 
of gene interactions and different expression patterns of the transcribed isoforms give 
versatility to protein function. The progress of the human genome project has increased 
database information of both the mapping elements in the genome as well as expressed 
sequences, and has offered tools for the positional mapping of genes as well as building 
blocks for gene discovery.   
In Finland, concomitant with the human genome project, significant progress has 
been made in identifying the genes underlying disorders of the so-called Finnish disease 
heritage. The concept of the Finnish disease heritage covers a wide spectrum of inherited 
conditions occurring more frequently in Finland than elsewhere. In the majority of these the 
founding disease-causing mutation has been found only in Finland, but in some the founder 
mutation has originated elsewhere. For instance, in myoclonic epilepsy of Unverricht-
Lundborg type (EPM1, Virtaneva et al., 1997) the founder mutation has been suggested to 
have been brought into Finland from North Africa (Moulard et al., 2002). On the other 
hand, Northern epilepsy (EPMR, Hirvasniemi et al., 1994) occurs exclusively in the Kainuu 
province in Finland and the disease-causing mutation has not been found elsewhere. The 
background for the positional cloning of Finnish disease heritage genes is built on the 
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extraordinary population structure and patterns of population movement during the early 
days of the inhabitation of Finland. The 36 Finnish disease heritage disorders can be 
divided into five subgroups, based on time of migration and geographic origin of the 
affected individuals (Norio, 2003a). Cohen syndrome belongs to the largest group, 
comprising about half of the Finnish disease heritage disorders, in which family origins are 
clustered in the area of late settlement (Norio, 2003a). Gene mutation enrichment in this 
group was initiated in the 1500s, when southern Savo farmers sought new cultivation land 
and populated the eastern, middle and northern parts of Finland (Norio, 2003a). The 
relatively small subisolates and low bi-directional gene flow between them provided 
conditions for the search for genes by linkage disequilibrium, which utilizes conservation 
of genomic regions around susceptibility loci.  
To date, the disease gene for 29 Finnish disease heritage disorders have been 
identified, and the disease gene locus is known for an additional five diseases. We can now 
include the Cohen syndrome gene COH1 in the growing group of Finnish disease heritage 
disorders in which the gene defect underlying the disease is described. The primary goals 
for this thesis work have been to identify the disease gene underlying Cohen syndrome, to 
set up methods for laboratory diagnosis, and to clarify the clinical definition of Cohen 
syndrome. The exceptional Finnish population structure has provided a firm ground for this 
endeavour. 
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1. Cohen syndrome 
Cohen syndrome (OMIM#216550) is a developmental disorder inherited as an autosomal 
recessive trait. The first description of this multisystemic disease in 1973 introduced a 
syndrome with peculiar faces and multiple affected organs (Cohen et al., 1973). The 
phenotype was described in three affected individuals, one sibling pair and an unrelated 
patient, who all had hypotonia, obesity, a high nasal bridge, and prominent incisors as well 
as mental deficiency. Mottled pigmentation of the retina was also described. In 1978, Carey 
and Hall published four additional cases with a Cohen syndrome phenotype. The 
involvement of chorioretinal dystrophy and isolated granulocytopenia in Cohen syndrome 
was described in 1984 (Norio et al., 1984), based on observations in nine Finnish patients.  
 
1.1. Cohen syndrome in Finland 
The incidence of Cohen syndrome in Finland is one in 105,000 nationwide, and one in 
60,000 when only the provinces with family histories of Cohen syndrome are considered 
(Norio, personal communication). This corresponds to the occurrence of approximately one 
affected newborn every two years. However, the number of new cases seems to be 
diminishing in Finland. This is probably due to migration from sparsely populated rural 
regions to densely populated communities. The geographical distribution of Cohen 
syndrome families covers practically the whole of Finland except the sparsely populated 
province of Lapland, but the highest prevalence is in the late settlement region including 
South Savo (Figure 1). To date, 34 Finnish patients have been clinically diagnosed with 
Cohen syndrome. 
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Figure 1. Geographical distribution of grandparental birthplaces of Cohen syndrome 
families in Finland. The area filled with gray color denotes the late settlement region in 
South Savo.  
 
1.2. Clinical manifestation of Cohen syndrome in Finnish patients 
Cohen syndrome is a clinical entity that has a complex multisystem involvement. In regards 
to diagnosis, the most important disease manifestations can be separated into four 
categories: affection of the central nervous system, dysmorphic bone development, retinal 
changes, and aberrance in leukocyte number. Both motor and mental developmental 
milestones are delayed and the intelligence quotient (IQ) varies from mild to severe mental 
deficiency (Kivitie-Kallio and Norio, 2001). The facial features include thick hair and 
eyebrows, flame-shaped lid-openings, prominent nose bridge, short philtrum and prominent 
and large upper central incisors (Norio et al., 1984). The faces of young Cohen syndrome 
patients have a charming general expression, whereas the facial features become coarser in 
FINLAND
late 
settlement
early
settlement
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older patients. Granulocytopenia is present intermittently, with the granulocyte value at low 
or below normal values resulting in relative lymphocytosis. Cohen syndrome is a non-
progressive disorder with the exception of retinal changes, which lead to a decrease in 
visual acuity and are usually present in patients from the age of five years, progressing 
finally to a severe visual defect (Norio et al., 1984). Progression of the eye manifestations 
follow a pattern similar to that in retinitis pigmentosa (RP), where the initial symptom is 
usually defective dark adaptation or "night blindness", followed by progressive constriction 
of visual fields i.e. "tunnel vision".  
Based on analysis of 29 Finnish patients presumed to be genetically homogenous, 
Kivitie-Kallio and Norio (2001) determined the essential features of Cohen syndrome as 
non-progressive psychomotor retardation, motor clumsiness, microcephaly, typical facial 
features (high-arched or wave-shaped eyelids, short philtrum, thick hair, and low hairline), 
childhood hypotonia and hyperextensibility of the joints, retinochoroidal dystrophy and 
myopia, and periods of isolated granulocytopenia. Additional findings frequently observed 
(>50% of Finnish Cohen syndrome patients) include reduced fetal activity, neonatal 
feeding difficulties, delayed puberty, short stature, high and narrow palate, small or absent 
lobuli of ears, narrow hands and feet, wide gap between toes one and two, brisk tendon 
reflexes, high-pitched voice, kyphosis, and a cheerful disposition (Kivitie-Kallio and Norio, 
2001).  
 
1.3. Phenotype heterogeneity and intrafamiliar variation in Cohen syndrome 
The clinical picture of Cohen syndrome has often been delineated. In many cases only 
some of the essential criteria are fulfilled (Balestrazzi et al., 1980; Goecke et al., 1982; 
Sack and Friedman, 1986; Massa et al., 1991), and few case reports depict patients who 
have a clinical picture consistent with Finnish Cohen syndrome patients (Carey and Hall, 
1978, Fryns et al., 1996, Horn et al., 2000; Okamoto et al., 1998, Warburg et al., 1990). Of 
the approximately 100 patients described only 20 appear to have a disease phenotype 
similar with Finnish patients, in regards to the main diagnostic criteria (Kivitie-Kallio and 
Norio, 2001). Chandler et al. (2003) reported an additional 33 Cohen syndrome patients 
from 22 families of British, Arabic and Dutch origin. These patients represented a group 
with clinical features compatible with Finnish patients with the exception of three patients 
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who had normal leukocyte counts. The wide variation in the Cohen syndrome phenotype 
has been proposed to be due to either allelic or locus heterogeneity (Kondo et al., 1990; 
Kivitie-Kallio and Norio, 2001; Chandler and Clayton-Smith, 2002). Chandler et al. (2003) 
proposed modified diagnostic criteria, and suggested that diagnosis of Cohen syndrome 
should be based on the presence of at least two of the essential signs in a patient with 
learning difficulties/mental retardation: typical facial gestalt, pigmentary retinopathy, and 
neutropenia (<2 x 10-9).  
Intrafamiliar variation in the Cohen syndrome phenotype has been reported on at 
least four occasions (North et al., 1985; Young and Moore, 1987; Carey and Hall, 1978; 
Horn et al., 2000). Kivitie-Kallio and Norio (2001) disputed the phenotype described in the 
first two of the above publications. The phenotype described in the other two is compatible 
with Finnish diagnostic criteria, and indicates phenotype variability in patients likely to be 
affected by the same mutation(s). Carey and Hall (1978) described four patients with Cohen 
syndrome, two of whom were sibs that differed in the presence of microcephaly and in 
facial habitus. Leukopenia, a sign considered to be essential in Cohen syndrome diagnosis 
(Kivitie-Kallio and Norio, 2001), was not evaluated in these patients. Whether they have 
Cohen syndrome is unproven, since no evidence of a COH1 locus association has been 
shown. Horn et al. (2000) reported a multiple consanguineous kindred of Lebanese descent 
with intrafamilial variability in disease severity (Horn et al., 2000). The phenotype in these 
patients, two brothers and a cousin, co-segregated with the COH1 locus in homozygosity 
mapping (Horn et al., 2000), and mutation analysis later confirmed the Cohen syndrome 
diagnosis (Hennies et al., 2004). These patients had moderate to severe mental retardation, 
microcephaly, short stature, and retinopathy. Neutropenia was absent. The presence of 
synophrys in these patients was exceptional in the Cohen syndrome facial gestalt, and the 
facial stigmata of these patients are proposed to be due to a different ethnogenic 
background (Horn et al., 2000).  
 
1.4. Clinical investigations in Cohen syndrome 
Due to the multitude of symptoms and clinical variability, Cohen syndrome has been 
suggested to be either a connective tissue disorder (Thomaidis et al., 1999) or a metabolic 
disorder (Okamoto et al., 1998). The components of the connective tissue disorder involve 
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an infrequently observed decreased left ventricular function arising in older patients, along 
with essential features like hypotonia, craniofacial dysmorphia and limb malformations 
(Kivitie-Kallio et al., 2001). Okamoto et al. (1998) proposed that the Cohen syndrome 
pathomechanism is associated with metabolic abnormality in three patients with essential 
signs and symptoms of Cohen syndrome and high levels of urinary hyaluronic acid. This 
sign was not present in Finnish patients, in whom the metabolic assay was negative. In 
addition, leukocyte morphology was normal and brain magnetic resonance imaging (MRI) 
was negative for any signs of lipid storage material accumulation within cells. Brain 
imaging in Cohen syndrome patients has not shown any gross pathological changes. The 
most significant observation in brain MRI has been a relatively enlarged corpus callosum 
(Kivitie-Kallio et al., 1998). This structure is made up of a substantial cluster of axonal 
fibers and works as a passage for nerve fibers between the two cerebral hemispheres. 
Recently, it has been reported that abnormal thinning of this part of the brain is associated 
with attention deficit syndrome (Pueyo et al., 2003) and alexithymia (Grabe et al., 2004), 
which is a manifestation of a deficit in emotional cognition. These observations link this 
part of the brain to the processing of emotions and support the proposed importance of this 
region in the development of the positive disposition of Cohen syndrome patients (Kivitie-
Kallio et al., 1999). 
 
1.5. Cohen syndrome differential diagnostics 
Several developmental disorders have been often confused with Cohen syndrome. These 
are described in more detail below. In many of them multiple disease genes are involved, 
three of them belonging to continuous gene deletion syndromes (Williams-Beuren 
syndrome, Prader-Willi syndrome, Angelman syndrome), and one of them being 
genetically heterogeneous syndrome (Bardet-Biedl syndrome). The number of genes 
involved partly explains the phenotypic complexity of these disorders. Cohen syndrome 
and Alström syndrome are both monogenic disorders. Mirhosseini-Holmes-Walton 
syndrome (Mirhosseini et al., 1972) has been proposed to be an allelic variant of Cohen 
syndrome (Norio and Raitta, 1986).  
 
REVIEW OF THE LITERATURE 21
1.5.1. Bardet-Biedl syndrome 
Bardet-Biedl syndrome (BBS; OMIM#209900, Bardet, 1920; Biedl, 1922) is probably one 
of the most difficult disorders to distinguish from Cohen syndrome in differential diagnosis. 
Like Cohen syndrome, BBS patients have a manifestation of mental retardation, 
pigmentary retinopathy, and similar facial dysmorphic features. These two disorders differ 
in loss of central vision in adolescence, polydactyli, male hypogenitalism, kidney 
malformations, renal dysfunction, diabetes mellitus, facial characteristics, and normal 
intelligence in some BBS patients. Granulocytopenia, present almost in all Cohen 
syndrome patients, is absent in BBS. Facial dysmorphism is inconsistent in BBS, and the 
most outstanding feature is deep-set eyes. Similar facial features to Cohen syndrome are: 
microcephaly, thick hair, coarse eyebrows, downward slant of the eyelids, broad nasal 
bridge, short philtrum, and prominent incisors. BBS is known to be a heterogeneous 
disorder with at least eight genes underlying the disease (Mykytyn et al., 2002; Nishimura 
et al., 2001; Fan et al., 2004; Mykytyn et al., 2001; Li et al., 2004; Slavotinek et al., 2001; 
Katsanis et al., 2000; Badano et al., 2003; Ansley et al., 2003). Additionally, the inheritance 
pattern is contradictory to Cohen syndrome, as a triallelic inheritance mode has been 
proposed for BBS when an additional mutation in a second locus was observed in some 
BBS patients (Katsanis et al., 2001; Burghes et al. 2001). The gene mutation diagnosis in 
BBS is elaborate due to several causative genes, which are large in size, and probably many 
additional disease genes are yet to be determined. 
 
1.5.2. Williams-Beuren syndrome 
Williams-Beuren syndrome (WBS; OMIM#194050, Williams, 1961; Beuren, 1972; Grimm 
and Wesselhoeft, 1980) has a dominant inheritance pattern, and while it shares clinical 
features of mental deficiency, short stature and cataracts, the cardiovascular symptoms 
involving supravalvular aortic stenosis and multiple peripheral pulmonary arterial stenoses 
are not observed in Cohen syndrome. A characteristic “ elfin”  face is also distinctive in 
Williams-Beuren syndrome, including short palpebral fissures, a stellate pattern in the iris, 
medial eyebrow flare, a depressed nasal bridge with anteverted nares, and thick lips (Jones 
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and Smith, 1975). Genes known to be causative in Williams-Beuren syndrome include ELN 
(Ewart et al., 1993), RFC2 (Peoples et al., 1996) and LIMK1 (Tassabehji et al., 1996). 
 
1.5.3. Prader-Willi syndrome and Angelman syndrome 
Prader-Willi syndrome (PWS; OMIM#176270, Prader et al., 1956) is similar to Cohen 
syndrome in respect to mental retardation, growth retardation, newborn hypotonia (which is 
more profound in PWS), small hands and feet, tapering fingers and strabismus. Facial 
characteristics are narrow bifrontal diameter, upslanted almond-shaped eyes, full cheeks, 
and diminished mimic activity due to muscular hypotonia. Central obesity, infrequent in 
Cohen syndrome, is a major diagnostic criterium in PWS (Gunay-Aygun et al., 2001; 
Kivitie-Kallio and Norio, 2001). Ocular hypopigmentation is proposed to be a result of 
misrouting of optical fibers (Creel et al., 1986). In Cohen syndrome the optic disk, fundus 
as well as the retina around the pigment formation is pale, due to atrophy of the retina 
(Kivitie-Kallio et al., 2000). Abnormal visual evoked potential (VEP) and nystagmus have 
been observed in both PWS and Cohen syndrome (Roy et al., 1992; Kivitie-Kallio et al., 
2000)  
Angelman syndrome (AS; OMIM#105830, Angelman, 1965) resembles Cohen 
syndrome in the presence of motor and mental deficiency, in general more severe in AS, 
hypotonia, abnormal choroidal pigmentation, large mandible and open-mouth appearance 
(Bower and Jeavons, 1967). Choroidal pigment hypoplasia has also been reported in these 
patients. Infrequently seen in Cohen syndrome patients, epileptic seizures are often present 
in AS along with ataxia and an abnormal ‘happy puppet’ behavioral pattern (North et al., 
1985, Thomaidis et al., 1999).  
The genomic region containing genes responsible for PWS and AS overlap on 
chromosome 15q11-q13 (Magenis et al., 1990). 
 
1.5.4. Alström syndrome 
Alström syndrome (ALMS; OMIM#203800, Alström et al., 1959) involves dystrophic 
retinopathy and obesity. In contrast to Cohen syndrome, ALMS patients are not mentally 
retarded. In addition, the progress of retinal degeneration differs. Central vision is 
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exceptionally affected early on (Russell-Eggitt et al., 1998). Other features constantly seen 
in ALMS, but not in Cohen syndrome, involve deafness, diabetes mellitus, and abnormal 
lipid metabolism (Charles et al., 1990). The ALMS1 gene on chromosome 2p13 is known to 
be causative (Collin et al., 2002, Hearn et al., 2002).  
 
1.5.5. Mirhosseini-Holmes-Walton syndrome 
Mirhosseini-Holmes-Walton syndrome (OMIM#268050, Mirhosseini et al., 1972, Mendez 
et al., 1985) clinically resembles Cohen syndrome, and whether these are clinically and 
genetically uniform entities has been disputed (Norio et al., 1986; Steinlein et al., 1991). 
These two disorders diverge considering the main clinical features only in respect to 
intermittent neutropenia, not reported in Mirhosseini-Holmes-Walton syndrome. The 
presence of mental retardation, ophthalmic changes with myopia, pigmentary retinal 
dystrophy and cataracts as well as typical craniofacial features, microcephaly, hypotonia, 
and hyperextensibility of joints in both Cohen and Mirhosseini-Holmes-Walton syndrome 
link these syndromes clinically.  
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2. Gene mapping and positional cloning 
 
2.1. Approaches for gene mapping projects 
The strategy for many molecular genetic research projects aiming at the identification of 
disease genes is to target the investigation to a specific, refined region in the genome. 
Identification of a disease gene on the basis of its location in the genome is called the 
positional cloning approach (Collins, 1992, 1995). In the positional candidate gene cloning 
approach determination of the gene localization is followed by analysis of a functionally 
relevant gene residing in the region. This method was first used in the identification of the 
CFTR gene underlying cystic fibrosis (Riordan et al., 1989). After completion of the total 
human genomic sequence positional cloning has been used almost without exception in 
gene hunting projects. 
 Earlier, functional cloning was a commonly used method. This approach is based 
on fundamental information about the basic biochemical defect without reference to 
chromosomal position. When the defective protein was known, knowledge of its amino 
acid sequence was utilized in the isolation of the disease gene. This approach was used, for 
example, to identify the HOGA disease-causing ornithine-d-aminotransferase gene (Valle 
and Simell, 1983). Another approach has been candidate gene cloning, which solely 
focuses on a group of known genes which may be suspected, on the basis of their function, 
to have a role in the pathophysiology of the disease, without previous knowledge of the 
location of the sought-after gene in the genome.  
The positional cloning approach consists of: 1) segregation analysis of the disease 
susceptibility locus by linkage-based methods; 2) linkage disequilibrium and haplotype 
analysis for refined disease gene locus determination; 3) physical mapping of the region; 4) 
identification of positional candidate genes in the sequence; 5) identification of the disease-
associated mutation.  
 
2.2. Linkage analysis 
The first step in positional cloning is to genotype the affected families and search for the 
segregation of affection status with the disease gene locus, by studying the familial 
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transmission of marker alleles at consecutive polymorphic loci. This necessitates statistical 
methods to interpret genome-wide data. The descriptive unit for the strength of linkage is 
the logarithm of odds i.e. lod score value, which is based on an equation developed by 
Newton E. Morton (1955).  
The lod score is the 10th base logarithm for the likelihood ratio or odds ratio for the 
likelihood of linkage at a given recombination fraction (q) between affection status and a 
marker locus to the likelihood of no linkage (Ott, 1985). In practice this ratio is computed 
for several values of recombination fraction. The frequency of one recombination event in 
100 meioses equals a map distance of one centiMorgan (1 cM   0.01 q) (Ott, 1991). This is 
1 Mb on average in physical distance, but it varies between males and females and depends 
on chromosomal location. The estimate for linkage is the sum of lod scores at a given 
recombination fraction in single families. The lod score calculation is dependent on both 
the mode of transmission and penetrance of the disease phenotype. The estimation of 
linkage for a single genomic locus depends only on the last meiosis and gives a reliable, but 
usually also relatively gross localization for the affection locus, the most likely distance 
between the loci studied being the recombination fraction at which the lod score is highest. 
In theory the probability of two recombinations in a region of 1 Mb is, on average, one in 
10,000, but depends on the true recombination frequency in a given region (Haldane, 
1919). This figure holds true for one meiosis, but a linkage study utilizes information 
collected from siblings and several affected families. Lod scores  3 are considered 
significant since they indicate 1:1000 odds that the linkage did not occur by chance. Lod 
scores < -2 are generally considered as significant evidence against linkage (Morton, 1955, 
Ott, 1991). 
 
2.3. Linkage disequilibrium and haplotype analysis 
Linkage disequilibrium (LD) and haplotype analyses have been used frequently to refine 
the initial disease gene locus in positional cloning of disease genes (de la Chapelle and 
Wright, 1998; Peltonen et al., 1999). The concept of LD can be interpreted as conservation 
of a region of ancestral origin in the genome extending over polymorphic loci around the 
disease-causing locus. LD can be applied in a single consanguineous family with a 
recessive monogenic trait (Lander and Botstein, 1987) and in isolated populations with 
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small numbers of founders. When a gene defect originating from a founder is enriched in a 
population with low gene flow from the outside certain alleles are over-represented in 
affected when compared to unaffected individuals. The strength of LD is dependent on the 
age of the mutation and the frequency of the associated allele in a control population. The 
extent of LD decreases over time at a rate proportional to the recombination rate 
(Hästbacka et al., 1992; Lehesjoki et al., 1993; de la Chapelle, 1993). The age of the 
mutation can be estimated applying the Luria-Delbrück-based algorithm (Hästbacka et al., 
1992). This method was further developed to calculate the distance between the affection 
locus and a polymorphic marker locus as a function of the proportion of disease-causing 
chromosomes descending from a common ancestor (Lehesjoki et al., 1993). The strength of 
the association is denoted by pexcess-value, which can be calculated using equation where 
the excess between a given allele frequency in disease-causing chromosomes and the 
frequency of the same allele in the general population is divided by the frequency of other 
alleles in the general population. In addition to manual linkage disequilibrium calculation, 
computer-based methods (DISLAMB for single locus and DISMULT for multiple loci LD 
calculation) have been developed (Terwilliger, 1995). The DISMULT program uses 
information from all marker loci simultaneously and has a built-in location parameter. The 
basic algorithm in both of these programs contain the parameter lambda (l), which is equal 
to the proportion of increase of allele i in the disease chromosomes, relative to its 
population frequency (Terwilliger, 1995).  
Haplotype analysis based on the concept of LD has been a method of choice in 
disease gene locus identification in many diseases more prevalent in Finland than elsewhere 
(de la Chapelle and Wright, 1998). An haplotype is a set of joined alleles in subsequent 
polymorphic loci in a given chromosome. Haplotype analysis is based on historical 
conservation of the genomic region around the disease gene in chromosomes sharing the 
common founder mutation. The length of the conserved haplotype is population-size and 
agedependent, and diminishes when recombinations or novel marker mutations occur in 
subsequent generations.  In Finland, the time elapsed between mutation founding and the 
present is long enough for refined mapping of the disease gene by using the information of 
historical recombinations (de la Chapelle and Wright, 1998).  
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2.4. Polymorphic markers 
Traditionally length polymorphisms (e.g. di-, tri-, and tetranucleotide repeats and VNTR 
markers) have been used in linkage, LD and haplotype analyses. In addition, the growing 
number of single nucleotide polymorphisms (SNPs) are nowadays being employed. SNP 
information is also utilized in loss-of-heterozygosity and haplotype-block analysis, and they 
can be studied as modifiers of the phenotype in genetic disorders. While length 
polymorphisms give comparatively higher analytical power, SNPs are in general more 
stable against de novo mutations (Ohashi and Tokunaga, 2003). The frequencies of 
mutation rates per generation for length polymorphisms is around 10-3~10-4 on average 
compared to the considerably lower mutation rate for SNPs, approximated to be 10-8 or less 
(Drake et al., 1998). The benefit of SNPs is in higher resolution genetic maps. SNPs are 
estimated to occur every 357 bp (January 2004 release of NCBI SNPdb), and one might 
expect 9.1 million SNPs in the genome. In contrast, there are currently 944,592 known di-, 
tri-, and tetranucleotide repeats (SSRD; URL: http://www.ingenovis.com/ssr/). 
 
2.5. Physical mapping 
Physical mapping of the human genome had two objectives during the human genome 
project. Firstly, to create framework maps for sequencing projects, and secondly to locate 
ESTs, and to identify and position the full-length transcripts identified by EST contigs or 
by other in silico- (see Review of the Literature section 3.3.) and in vitro-based methods. 
Before the human genome sequence became available, physical maps were constructed 
with genomic libraries in which the human genome is fragmented in genomic clones 
containing human DNA inserts. Genomic cloning vectors designed for this purpose were 
yeast artificial chromosomes (YACs, Burke et al., 1987), bacterial artificial chromosomes 
(BACs, Shizuya et al., 1992), bacteriophage P1-derived chromosomes (PACs, Ioannou et 
al., 1994) and cosmids (Meyerowitz et al., 1980). The size of the insert depends on the 
vector, with the largest inserts of ~500 kb cloned in YACs, and the smallest ~48 kb in 
cosmids. 
Another method developed for genomic mapping was radiation hybrid (RH) 
mapping (Goss and Harris, 1975; Cox et al., 1990: Walter et al., 1994). The RH method is 
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based on random fusion of irradiated human cells with hamster recipient cells after 
fragmentation of a donor genome by radiation (Goss and Harris, 1975). DNA from 80-100 
independent hybrids is analyzed for the presence or absence of DNA markers of interest, 
and the mapping unit distances are calculated using a computer program designed to handle 
statistical data analysis of joined linkage groups (Boehnke et al., 1991, 1992; Lunetta and 
Boehnke, 1994; Slonim et al., 1997). The centiRay (cR) unit is equal to 280 kb in the 
Whitehead Institute GeneBridge RH panel (Gyapay et al., 1996) and 25 kb in the Stanford 
G3 panel (Stewart et al, 1997). The mapping unit order is computed by applying the 
minimized number of obligate chromosome breaks. The RH method has higher resolution 
than linkage mapping and is more robust than the cloning vector-based physical mapping 
approach (Bishop and Crockford, 1992). The advantage to linkage analyses is its ability to 
estimate a map position also for non-polymorphic markers.  
 
2.6. Identification of coding sequences 
Prior to the availability of annotated human genome sequence one had to rely on different 
laboratory methods to identify genes in genomic clones mapped to the region of interest. 
These include: identification of CpG islands (Gardiner-Garden and Frommer, 1987), cDNA 
direct selection (Lovett et al., 1991), and exon amplification (Duyk et al., 1990). To ensure 
the identification of as many genes as possible one usually had to apply many different 
methods simultaneously. Concominant with the progress of the human genome project a 
constantly growing number of ESTs, pinpointing the localization of coding sequences, were 
deposited in the databases. Now that the genomic location at the majority of human genes is 
available in published gene maps, the recognition of transcript units from the genomic 
region of interest by biocomputing has become possible. This has made gene identification 
easier and has replaced in vitro-based techniques for gene isolation. The first human gene 
map was published in June 1996 (Schuler et al., 1996). Mapping data was based on YAC -
based contigs and RH maps, which were integrated into the framework human gene map 
containing 16,000 human genes and 1000 polymorphic genetic markers (Schuler et al., 
1996). This preliminary map was followed by the human genome consortium release of 
30,000 human genes in October 1998 (Deloukas et al., 1998). 
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Today, the entire human genomic sequence is available as a sequence contig, and 
the accurate position of transcript units can be determined from the mapping data present in 
an electronic form in sequence databases. To make it easier to interpret the mapping data, 
graphical interfaces for data mining have been developed in which the position of the 
mapping units and their relative distances to each other within a specific genomic region 
can be seen simultaneously. The latest assembly of human genome data is available from 
the University of California Santa Crutz (UCSC; URL: http://genome.ucsc.edu/cgi-
bin/hgGateway), which is based on the National Center for Biotechnology Information 
(NCBI) Build 34 human reference sequence produced by the International Human Genome 
Sequencing Consortium (Lander et al., 2001). The UCSC genome browser also shows 
alignment of human sequence to chimpanzee, mouse, rat, and chicken as well as Fugu fish 
genomic sequence. Ensemble (http://www.ensembl.org/), a joint effort of EMBL-EBI and 
the Sanger Center, contains larger sets of genomic data, presently of 12 different species. 
 
2.7. Mutation analysis 
The final step in positional cloning is to identify disease-associated mutations in patient 
samples in genes identified from the region. Several methods exist with different 
sensitivities and costs. Methods used in mutation analysis include Southern (Southern, 
1975) and Northern blot (Sambrook et al., 1989) analysis, single-strand conformation 
polymorphism analysis (SSCP; Orita et al., 1989), and denaturing gradient gel 
electrophoresis (DGGE; Fischer and Lerman, 1983). Any change detected by the above 
means has to be confirmed by sequencing to characterize the variation at the nucleotide 
level and for this reason sequencing is often used as a primary method. These methods are 
nowadays largely replaced by semi-automated mutation analyses, which are suitable for 
analysis of larger sample sets. Semi-automated techniques include heteroduplex analysis by 
denaturing high-performance liquid chromatography (DHPLC; Oefner and Underhill, 
1995), and automated sequencing, which is performed by capillary electrophoresis (Karger, 
1996). In addition, for large-scale diagnostic mutation analysis, minisequencing (Jalanko et 
al., 1992) and ligation-based methods e.g. oligonucleotide ligation assay (OLA; Alves and 
Carr, 1988; Landegren et al., 1988) and ligation chain reaction (LCR; Barany, 1991) have 
been developed. 
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3. Bioinformatics and gene identification tools 
 
3.1. Strategy of human genome sequencing 
Human genome sequencing was accomplished by a publicly funded project, primarily led 
by National Institutes of Health (NIH) and the U.S. Department of Energy, and the 
commercial Celera led project. The fundamental methodological difference between them 
was in the sequence assembly strategies. Celera used a whole-genome shotgun sequencing 
method (Venter et al., 1998) whereas the public consortium relied on a map-based 
approach. The public human genome project was carried out in three phases: 1) A mapping 
phase, when the first established genetic maps allowed the use of intermarker order and 
distances in physical map construction. The physical maps consist of clones of large 
genomic fragments arranged in contigs with overlapping marker loci. 2) A sequencing 
phase, which used automated sequencing of selected single clones covering the human 
genome in shotgun cloned genomic libraries, and in silico-assembly of the produced 
sequence. 3) Utilization of obtained genomic sequence data to gain knowledge about 
human sequence variation, gene identification, and elucidation of genomic organization by 
cross- and inter-species comparisons. These stages and the goals of this academically led 
project were reached over a twelve-year period (Collins et al., 2003), although analyses of 
the genomic sequence obtained and interpretation of the results are still continuing.  
 
3.2. Tools to assemble sequence data in large sample sets 
The assembly of provisional sequence from the library clones to genomic contigs 
demanded high biocomputing capacity. It also required the development of more efficient 
in silico-based programs for effective sequence quality analysis and alignment. Unix-based 
programs (http://www.phrap.org) for quality estimation (Phred; Ewing et al., 1998a; Ewing 
and Green, 1998b), sequence assembly (Phrap; Green, unpublished) and alignment 
(Consed; Gordon et al., 1998) were utilized to compose the single reads into sequence 
contigs. A quality assessment criterion for this was, depending on the sequencing center, 
eight- to ten-fold coverage of overlapping sequences. 
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3.3. Gene sequence identification 
 
3.3.1. Sequence homology programs 
The exponential growth of sequence information in databases has necessitated the 
development of more powerful computational methods to identify homologous sequence 
patterns. Sequence alignment has been used in genomic localization of a given sequence, in 
the search for transcript sequences, and for pattern similarity recognition of functional 
elements. The similarity search programs, which have evolved from simple algorithms for 
sequence alignment (FASTA; Lipman and Pearson, 1985), have resulted in increased 
calculation capacity. The development from the single-pass database-search method, basic 
local alignment search tool (BLAST; Altschul et al., 1990), to an iterated profile-based 
search method, PSI-BLAST (Altschul et al., 1997), which utilizes position-independent gap 
scores of Gapped Blast search, has permitted local blast searches with gapped alignments. 
This improvement has resulted to 10-100 times faster sequence alignment (Altschul and 
Koonin, 1998). While the Blast program similarity search is based on the length of 
continuous homology between the sequences, the Gapped Blast search also recognizes 
similarities that contain gaps in the middle of the homologous region.  The cutting of the 
query sequence into smaller units in repeated similarity searches has enhanced sensitivity in 
similarity identification of sequences having intermittent segments of low homology.  
 
3.3.2. Exon prediction algorithms 
Several biocomputing tools to extract gene sequences from the entire genomic information 
have been developed. Prediction programs can be separated into those that utilize general 
models for gene structure and the regulatory elements in the genome (ab initio or intrinsic 
methods), and those that are based on cross- and intra-species conservation of protein 
coding sequences (extrinsic methods) (Korf et al., 2001). A third, integrated, approach is 
the homology-based method in which cross- or intra-species sequence comparisons are 
combined with structural information (e.g. Procrustes; Gelfand et al., 1996).  
Signal detection and codon statistics based intrinsic methods utilize only the 
structural information of the genomic organization of the genes (Mathé et al., 2002). This 
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compositional and signal information, organized in training sets based on known genes, is 
used in the prediction of exons by intrinsic methods algorithms. The pattern recognition 
algorithms used by intrinsic methods are neural networks, discriminant analysis, and 
hidden Markow models (Murakami and Takagi, 1998). Homology search-based extrinsic 
methods compare the genomic sequence to known gene sequence at either the genomic, 
cDNA or protein level (Mathé et al., 2002). The basic assumption behind this method is 
that coding regions evolve slower than non-coding regions. 
In silico exon prediction can only be suggestive, and all these methods have 
disadvantages. The exon prediction programs utilizing intrinsic approaches in exon 
discovery have a tendency to more reliably identify genes residing in GC-rich regions, 
when the preference for identification is of medium-size exons (length range between 70 
and 200 nucleotides) and in internal exons, which do not contain start and stop signals for 
protein coding (Rogic et al., 2001). The weakness of extrinsic method is that genes without 
homologues in databases are missed and comparison of translated genomic sequence to 
protein sequence is sensitive to frameshift errors. Single programs have differences in 
accuracy, but the best prediction result can be obtained by combining the information from 
several programs (Murakami and Takagi, 1998).  
 
3.3.3. CpG islands 
Another approach to identify putative gene elements within genomic sequence is to search 
for regions having high, over 50%, C+G content i.e. CpG islands. In humans and mice, 
approximately 60% of all promoters co-localize with CpG islands devoid of methylation 
(Antequera, 2003). GC-rich regions usually represent upstream regulatory segments of 
genes, working possibly both in transcriptional and post-transcriptional regulation of gene 
expression, and are positioned either upstream or downstream from transcription factor 
(TF) binding sites (Gardiner-Garden and Frommer, 1987). Sometimes this regulatory 
element overlaps with the CpG island. Provisionally unmethylated CpG islands are 
detected in promoter regions of housekeeping and regulated genes (Bird, 1986, Larsen et 
al., 1992). The CpG island is methylation-free in somatic cells and is profusely associated 
with genes regularly activated (Ghazi et al., 1992). The exception for this rule is observed 
in some oncogenes (e.g. French et al., 2003; Strathdee et al., 2001). CpG methylation 
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results in silencing of the associated gene. Examples of computer programs developed to 
discover CpG island regions are CpG Island (Gardiner-Garden and Frommer, 1987), 
CpGPlot (Larsen et al., 1992) and accessory applications in the EMBOSS package 
(http://www.no.embnet.org/Programs/SAL/EMBOSS/). The CpG promoter program 
(Ioshikhes and Zhang, 2000) discriminates promoter-associated and non-associated CpG 
islands. 
 
3.3.4. Expressed sequence tags (ESTs) 
ESTs are usually partial sequences of cDNA clones representing small segments of 
expressed genes. Often they correspond to the 5’-coding or 3’-untranslated end of the gene. 
They are used mainly in gene discovery and physical mapping of genes.  
The Institute of Genome Research (TIGR) was the first to start high-throughput 
cDNA library random sequencing in 1991 (Adams et al., 1991). Today, the gene indices 
(http://www.tigr.org/tdb/tgi/) contain over 3.7 million (835,000 of them human) unique 
EST sequences from 82 species. Another EST source is the NCBI EST database 
(http://www.ncbi.nlm.nih.gov/dbEST/index.html). The total number of ESTs collected in 
the NCBI databases to date is over 24 million (around six million of them human) and this 
figure grows rapidly. Because of the increasing number of EST sequences the Unigene 
collection of genes (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) was 
developed in NCBI in 1995 (Boguski and Schuler, 1995) (this database combines the ESTs 
released and creates clusters of overlapping gene sequences). The EST sequences collected 
in the Unigene database were converted to sequence tagged sites (STSs), which were used 
as a source for the release of the first gene map in 1996 (Schuler et al., 1996).  
In addition to exploiting ESTs as tools to identify transcript units in the genome 
they have been used in many other applications as well. ESTs are utilized in the 
determination of expression profiles of genes (e.g. Gress et al., 1996; Khan et al., 1999). 
ESTs have also been useful in determination of alternatively spliced isoforms of transcripts, 
and for elucidation of their expression pattern in different libraries or tissues (Thanaraj et 
al., 2004; Pospisil et al., 2004). Functional annotation of ESTs has helped in determination 
of gene associations with metabolic and signaling pathways and gene ontology 
classification of transcripts (e.g. Whitfield et al., 2002; Lee et al., 1999). ESTs are also of 
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use in detection of single nucleotide polymorphisms (SNPs), which sometimes function as 
modifiers of the phenotype (Picoult-Newberg et al., 1999).    
Although ESTs have greatly enhanced the discovery of novel genes they also have 
many disadvantages. Some EST databases contain cDNA sequences from cancer cell-line 
cDNA libraries, in which the transcript sequences can be highly reorganized and do not 
represent the intact transcript sequence. The accuracy of the EST sequences is dependent on 
the purity of the mRNA libraries. A small amount of genomic contamination can lead to 
cloning of the genomic insert instead of the cDNA fragment. The cDNA libraries are also 
susceptible to bacterial and viral contamination. The technique using poly-T probes to 
identify poly-A tails of transcripts is used for ‘fishing‘ of putative transcript sequences and 
might lead to identification of poly-A regions of genome not associated with the expressed 
sequence. The mRNA libraries can also contain immature transcripts not yet processed to 
the mature form, containing intronic sequences.  
 
3.4. Protein characteristics predicting programs 
Nowadays bioinformatics is more and more concentrated on understanding functions and 
utilities at the molecular, cellular and organism levels (Kanehisa and Bork, 2003). For the 
prediction of protein function in cellular processes programs such as PSORTII (Nakai and 
Kanehisa, 1992) have been designed, which search for protein sorting signals and cell 
localization site-determining patterns in amino acid sequence. The vast amount of 
information available demands integration of protein data under one structured database, 
such as InterPro (Apweiler et al., 2000) and the larger ensemble in the Proteome Analysis 
database (Pruess et al., 2003), which combines information of protein families, domains, 
sites, and functions of complete genomes. The protein domain family database, ProDom 
(Gouzy et al., 1999), aligns proteins by conserved domain structures, and arranges the 
branching of protein sub-classes in a phylogenetic tree. The applications for ProDom 
include protein-protein interaction studies and structural genomics (Corpet et al., 2000). In 
the future, functional predictions will utilize the knowledge base of three-dimensional 
folding unit structure in functional domain structure identification. The structural 
classification of proteins (SCOP) database (Barton, 1994) compiles data from three-
dimensional protein models according to folding patterns (Reedy and Bourne, 2003). The 
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three-dimensional position-specific scoring matrix (3D-PSSM) program is an application 
that utilizes protein fold profiles from the SCOP database to predict the folding pattern for a 
query protein by coupling 1D- and 3D-protein structures with protein secondary structure 
(Kelley et al., 2000). The constructed model facilitates the prediction of protein function. 
However, these computer-based predictions have restrictions in protein modeling and 
functional analysis. For instance, the huntingtin and orphan proteins are examples of 
proteins with novel functions not predictable by in silico -methods.  
 
3.5. Comparative genomics 
The development of cDNA sequence databases has allowed the integration of data for 
cross-species comparison of sequences, gene intron/exon identification and detection of 
multiple transcripts. Cross-species comparison of the regulatory regions for gene 
expression has helped to identify transcription factor binding sites, which should show high 
similarity in non-coding regions with generally low conservation between species. Liu et al. 
(2004) proposed an average identity of 69.5% for 127 human and mouse representative 
gene regulatory elements, with 81% of elements having over 50% similarity. This is 
considerably higher conservation than that of “ background sequences”  (Liu et al., 2004). 
To date, regulatory elements have been identified by applying comparative genomics for 
several human disease genes (Hansson et al., 2003; Zatyka et al., 2002; Touchman et al., 
2001; Loots et al., 2000).  
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AIMS OF THE STUDY 
 
I The primary aim was to identify and characterize the gene (COH1) responsible for 
Cohen syndrome by positional cloning, and to detect the mutations in Finnish and 
non-Finnish Cohen syndrome patients.  
II The second aim was to correlate the clinical phenotype with the COH1 gene 
mutations. 
III The third aim was to establish uniform clinical criteria for Cohen syndrome and to 
facilitate the establishment of a gene test to support the clinical diagnosis. 
IV The fourth aim was to predict the function and subcellular localization of the COH1 
protein by in silico–based methods, and deduce the COH1 protein involvement in 
biological processes through the known function of the protein homologs. 
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SUBJECTS AND METHODS 
 
1. Subjects 
In total, 75 Cohen syndrome families, 21 of them Finnish (Figure 2), were included in the 
study. The majority of the patients, except patients in families 15-18, were involved in a 
nationwide clinical study of Cohen syndrome (Kivitie-Kallio and Norio, 2001) and were 
diagnosed by Doctor Satu Kivitie-Kallio at the Helsinki University Central Hospital and 
Professor Reijo Norio at the Family Federation of Finland. Patients in 31 Cohen syndrome 
families from the United Kingdom were diagnosed by clinical geneticists in a large clinical 
cohort study over a two year period (1999-2001) in St. Mary’ s Hospital, Manchester. 
Chandler et al. (2003) published the clinical phenotype of these patients. Additionally, we 
studied four Belgian families from Professor Jean-Pierre Fryns in Leuven University. The 
clinical data of these three patients have been published earlier (Fryns et al., 1996). Six of 
the eight unpublished Israeli families are from Doctor Varda Gross Tsur in Jerusalem 
Childrens Hospital. Two Danish families, one of them published (Warburg et al., 1990), 
were from Doctor Mette Warburg in Glostrup. Doctor Matthew L. Warman in Cleveland, 
Ohio, USA, sent the Amish family samples to us. Of the remaining eight families, four are 
from Germany, and one each from Holland, Austria, the USA and Syria. The set of control 
samples used in this study included 98 Généthon CEPH and 56 Finnish Red Cross samples, 
which were provided to us courtesy of Doctor Pertti Sistonen. The Cohen syndrome 
patients or their lawful custodians signed an informed consent form for participation in the 
research, and the study was reviewed and approved by the ethics review board of the 
Department of Medical Genetics at the University of Helsinki. 
 
 
 
 
 
 
 
 
                                                                                                  SUBJECTS AND METHODS 38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pedigrees of 21 Finnish Cohen syndrome nuclear families included in the study. 
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2. Methods 
Table 1. Laboratory methods 
 
Material or method Study Reference 
Polymerase chain reaction (PCR) I, II, III, IV Weber and May, 1989 
RT-PCR II, IV Ohara et al., 1989 
Haplotype analysis I, II Ramsay et al., 1993 
Linkage disequilibrium (LD) 
analysis 
I Hästbacka et al., 1992; 
Lehesjoki et al., 1993 
DNA extraction  I, II, III, IV Sambrook et al., 1989 
Mutation analysis II, III, IV See Review of the Literature 
section 2.7.  
Linkage analysis I Botstein et al., 1980; Ott, 1991 
Physical mapping II, unpublished Brown and Bird, 1986; Green and 
Olson, 1990 
Direct sequencing II, III, IV Maxam and Gilbert, 1977; Sanger 
et al., 1977 
Polyacrylamide gel 
electrophoresis (PAGE) 
I, II Maniatis et al., 1975 
Silver staining of polyacrylamide 
gels 
I, II Bassam et al., 1991 
Single strand conformational 
polymorphism (SSCP) gel 
electrophoresis 
II, IV Orita et al., 1989 
Agarose gel electrophoresis unpublished Aaij and Borst, 1972 
Restriction enzyme digestion 
analysis 
II Arber, 1974; Nathans and Smith, 
1975 
Northern blot analysis II Sambrook et al., 1989 
Yeast artificial chromosomes 
(YACs) 
unpublished Burke et al., 1987 
Bacterial artificial chromosomes 
(BACs) 
II, unpublished Shizuya et al., 1992 
P1 clones (PACs) unpublished Ioannou et al., 1994 
TA cloning IV Hu, 1993 
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Table 2. Programs and statistics used in computational analysis  
 
Program Study Reference URL  
LINKAGE v.5.0 package I, III Lathrop et al., 1985 ftp://linkage.rockefeller.edu/softwar/linkage  
Luria-Delbrück-based method I Hästbacka et al., 1992, 
Lehesjoki et. al., 1993,  
 
DISMULT v.2.1 I Terwilliger J.D., 1995 ftp://linkage.cpmc.columbia.edu/ 
software/ 
 
BLAST II Altschul et al., 1990 http://www.ncbi.nlm.nih.gov/ 
BLAST/ 
Align II Pearson and Lipman, 1988 http://molbiol.soton.ac.uk/compute/ 
align.html 
Prosite II Hofmann et al., 1999 http://expasy.hcuge.ch/sprot/prosite.html 
ProDom II Gouzy et al., 1999 http://protein.toulouse.inra.fr/prodom/current/
html/home.php 
Kyte-Doolittle hydrophobicity 
profile 
II Kyte and Doolittle, 1982 http://us.expasy.org/cgi-bin/protscale.pl 
SOPMA II Geourjon and Deleage, 1995 http://npsa-pbil.ibcp.fr/cgi-bin/ 
npsa_automat.pl?page=/NPSA/ 
npsa_sopma.html 
PSORT II II Nakai and Kanehisa 1992 http://psort.nibb.ac.jp 
TMAP II Persson and Argos 1994 http://www.mbb.ki.se/tmap/ 
CAP3 II Huang and Madan 1999 http://www.tigr.org/tdb/tgi/software/ 
ClustalW II Thompson et al., 1994 http://www.ebi.ac.uk/clustalw/ 
UCSC Human genome browser II Kent et al., 2002; 
Kent, 2002; 
Karolchik et al., 2003 
http://genome.ucsc.edu/cgi-bin/hgNear 
CpGProD  unpublished Ponger and Mouchiroud, 2001 http://pbil.univ-lyon1.fr/software/ 
cpgprod_query.html 
MATCH 
(interconnected with 
TRANSFAC® database) 
unpublished Wingender et al., 2001 http://www.gene-regulation.com/pub/ 
programs.html#match 
SIM unpublished Huang and Miller, 1991 http://www.expasy.org/tools/sim-prot.html 
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RESULTS AND DISCUSSION 
 
1. Fine-mapping of the COH1 gene 
 
 
1.1. Linkage, and linkage disequilibrium fine-mapping of the COH1 locus (I) 
We applied linkage analysis to further refine the COH1 locus mapped by Tahvanainen et al. 
(1994). We were able to narrow the previous 10 cM COH1 region bordered by markers 
D8S270 and D8S521 by only 0.4 cM, to a 9.6 cM region flanked by markers D8S1699 and 
D8S1714. The allele sharing observed in Finnish COH1 chromosomes prompted 
investigation of this region by LD and haplotype analysis. LD was investigated with eight 
polymorphic markers non-recombinant with COH1. Highly significant (p<0.001) LD was 
observed with markers D8S559 and D8S1762 (I, Table 1). Additionally, the frequencies of 
disease-associated alleles of marker loci D8S506, D8S257, and D8S546 were significantly 
higher in Cohen syndrome patients (0.001<p< 0.01) than in control cohorts. A DISMULT 
multipoint LD analysis (Terwilliger, 1995) graph showed a one peak curve, and a highest 
lod score of 9.2 at map position 0.2 cM proximal to D8S1808 (I, Figure 3). The 99% 
confidence interval for this position covered a 3.7 cM region, 1.2 cM telomeric of D8S506 
to 1.1 cM centromeric of D8S1714. 
 
1.2. Initial haplotype analysis in Finnish Cohen syndrome patients (I and unpublished) 
Haplotypes were constructed manually, and 25 of 29 disease chromosomes were assumed 
to represent a conserved major haplotype (I, Table 2). COH1 gene localization by 
haplotype analysis to an interval flanked by markers D8S1808 and D8S546 was based on 
observation of a shared allele 5 at marker locus D8S1762 (I, Table 2). This occurred in 87% 
(27/31) of the COH1-bearing chromosomes (I, Table 1) and in only 38% (9/24) of control 
chromosomes. In addition, the allele combination 2-5-7 in three consecutive marker loci, 
D8S1808, D8S1762, and D8S546, was seen in 24 disease chromosomes (I, Table 2) and in 
only two of 28 Finnish control chromosomes (data not shown). Based on the hypothesis 
that the majority of Cohen syndrome patients have one single founder mutation the 
haplotype data pinpointed the D8S1808-D8S546 interval as the most likely region and the 
initial gene identification searches were focused within this area.  
                                                                                               RESULTS AND DISCUSSION 42
At the time of the first haplotype analysis, the order of markers and their physical 
map distances (Figure 3) were based on the Généthon genetic and Whitehead Institute 
physical YAC map (Dib et al., 1996). Subsequently, the sequence-based physical map 
(Lander et al., 2001; Venter et al., 2001; Figure 3) revealed that the original position of 
markers was incorrect. Moreover, subsequent studies with additional Cohen syndrome 
families and a denser marker map proved the initial localization to be incorrect, and 
allowed localization of COH1 more proximally, in a region flanked by markers D8S257 
and D8S559 (see Results and Discussion section 1.4.). 
 
 
Figure 3. Relative order and intermarker distances of microsatellites around the COH1 
gene locus as presented in three different sources (Généthon genetic map, USCS physical 
map, and Whitehead Institute yeast artificial chromosome (YAC) map). The UCSC map is 
based on genomic sequence of the region. The interval in which the COH1 gene was 
eventually identified (see Results and Discussion section 1.5.) is marked with a bold lines. 
Significant (p<0.001) linkage disequilibrium was observed with the two microsatellites 
indicated by a dark gray background color. The connecting lines between the maps indicate 
the relative positions of each marker. 
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1.3. Physical map of the initial COH1 locus (II and unpublished data) 
We first focused the physical mapping and gene identification efforts to the region between 
D8S559 and D8S1714, covering a region of 3.8 cM and 700 kb, implicated by the initial 
haplotype mapping data. A low-resolution YAC contig was composed of CEPH mega-
YACs (Cohen et al., 1993; Chumakov et al., 1995) onto which STSs from the region 
indicated by the haplotypes were mapped (Figure 4). Information available in public 
databases allowed the selection of YAC clones containing genomic markers residing within 
the region of interest. Eight of ten YACs were found to be non-chimeric and did not have 
large deletions. Our ultimate purpose was to build a gene map that would provide 
information that could be applied in the identification of candidate genes and in the longer-
term goal of sequencing this region. For this the smaller and more stable BAC and PAC 
clones were ideal. Eight BAC and three PAC clones were found to reside within the region 
(Figure 4), and one of these, the 162-kb BAC clone 476J3 containing the COH1 region 
refined by initial haplotypes around D8S1762, was purchased from Genome Systems, and 
eventually sequenced by us at the Ohio State University. Twelve ESTs were positioned in 
the physical map. Of these, four represent previously annotated genes: Homo sapiens 
polymerase (RNA) II (DNA directed) (POLR2K) represented by WI-8892, SPAG1 by WI-
7256, a pseudogene for Glyceraldehyde 3-phosphate dehydrogenase by WI-14243 and a 
potassium channel-like gene by WI-12835. 
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Figure 4. Physical map of the approximately 1.1 Mb genomic region flanked by WI-8892 and D8S521, comprising ten YAC, 
eight BAC, and three PAC clones. The larger deletions in clones are shown in brackets, and missing single marker sites are in 
parentheses. The length scale is based on the physical distance between WI-8892 and D8S521 as indicated in the UCSC May 
2004 assembly. A thick line indicates the BAC clone sequenced by us. Marker D8S257, defining the proximal boundary of the 
true COH1 region (see Figure 5), resides outside this area ~ 1.8 Mb away, and COH1 ~ 276 kb proximal to WI-8892. The 
physical map overlaps with the true COH1 region (see Results and Discussion section 1.4.), which is flanked on the telomeric 
side by marker D8S559. Of the eight transcripts initially screened for mutations in Cohen syndrome patients, four resides within 
this physical map. Nucleotide changes are shown in table 4. 
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1.4. Extended haplotype analysis in Finnish Cohen syndrome patients (II, unpublished 
data) 
As the extensive search for a gene defect within the region flanked by markers D8S1808 
and D8S546 (I, Table 2) did not result in COH1 gene identification, we extended the search 
to include the genes surrounding this region. Concomitantly, we typed an extended panel of 
Finnish patients with novel microsatellite and SNP markers. A rare amino acid-changing 
nucleotide substitution (c.704G>A; p.Ser235Asn denoted DORFIN/PvuII, Table 3) was 
found in one of the genes under study, the DORFIN gene (Niwa et al., 2001), and was 
present in 29 of 39 Finnish COH1-bearing chromosomes (Table 3), but not in 112 Finnish 
or 196 CEPH control chromosomes. The aforementioned 29 affected chromosomes 
included the majority (28/31) of initially presumed main COH1 mutation carrying 
chromosomes and one affected chromosome in a newly diagnosed patient (No. 32 in Table 
3). The rarity of the allele at the DORFIN/PvuII locus was additional proof for strong LD, 
which led us to search for and genotype novel single nucleotide polymorphisms (SNPs) 
more upstream from this marker site. The haplotypes constructed associated chromosome 
no. 32 with the major haplotype and excluded three chromosomes, which were previously 
assumed to carry main mutation. This directed our search for COH1 proximal to DORFIN 
and helped to define a new, approximately 2 Mb, COH1 region flanked by D8S257 and 
D8S559 (Table 3). We did an extended mutation search in the DORFIN gene by exon-by-
exon sequencing, but this did not reveal additional changes in Cohen syndrome patients 
implying that DORFIN was unlikely to be the gene for Cohen syndrome. However, we 
found eight additional polymorphic sites predicting four amino acid changing variants and 
four silent changes (Table 4).   
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Table 3. Haplotypes in 39 chromosomes of 20 Finnish Cohen syndrome patients. The 
haplotypes indicate two possible locations for COH1. The initially assumed localization of 
COH1 (chromosomes 1-31) is framed. Conserved founder haplotypes refining the true 
COH1 critical region based on novel haplotype data and observed COH1 mutations are 
shown in blue background color (chromosomes 1-28 and 32). These were observed in 76% 
of putatively unrelated Finnish Cohen syndrome chromosomes and were all associated with 
the founder mutation. Conserved haplotypes framed in chromosomes 33-35 share a second 
mutation. Markers D8S257 and CA-5, with CA-CEN1 located in COH1 intron 33, flank the 
COH1 gene. 
 
 
 
 
 
 
 
 
 
 
1.5. Physical map of the true COH1 locus (II and unpublished data) 
After the genomic region for the COH1 gene indicated by initial haplotype analysis was 
thoroughly examined for positional candidate genes and the COH1 mutation, the novel 
haplotype data showed a new position for the COH1 gene. At the time, a relatively good 
sequence-based physical map was available for this region, and a more exact map was 
being produced by the public project. The approximately 2 Mb critical interval for COH1 
defined by the extended haplotype analysis (Table 3) contained, in addition to the COH1 
gene, seven genes: six previously reported genes, and one partial transcript (Figure 5).  
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Figure 5. Location of six previously characterized genes (STK3, OSR2, COX6C, POLR2K, 
SPAG1, DORFIN), and partial mRNA of the gene encoding F-Box protein (BC028709) in 
an approximately 2.0 Mb genomic region flanked by D8S257 and D8S559. These seven 
transcripts were screened for mutations in Cohen syndrome patients. These genes and the 
identified nucleotide changes are shown in Table 4. None of these genes were identified as 
COH1. 
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Table 4. Summary of the fifteen genes studied for mutations in Cohen syndrome patients 
before the identification of the COH1 gene.  
 
Gene (mRNA/protein  
ID) and map position*1 
(Mb) 
References Transcript/protein variant 
DORFIN (101.2-101.3) 
(AB029316, Q9NV58) 
Niwa et al., 2001; Niwa et al., 
submitted 
[c.704G>A; p.Ser235Asn];[c.601T>G; p.Tyr201Asp]; 
[c.758A>C;p.His253Pro];[c.1012G>C ; p.Asp338His]; 
[c.1091A>T; p.Gln364Leu];[c.105C>T;p.His35His]; 
[c.666G>A; p.Pro222Pro];[c.843C>T; p.Arg281Arg]; 
[1083A>C; p.Ile361Ile] 
SPAG1 (101.1-101.2) 
(AF311312, Q07617)  
Zhang et al., 1992; Lin et al., 2001; 
Lin et al., unpublished 
[c.ins1059_1060GAC; p.Lys353_Ser354insAsp];  
[c.2715G>A; p.Ser905Ser] 
Putative F-Box gene (101.1) 
 (BC028709) 
Strausberg, unpublished - 
STK3 (99.4-99.8) 
(U26424, Q13188) 
Creasy and Chernoff, 1995; Creasy, 
unpublished 
- 
OSR2 (99.9) 
(AK074518, Q8N2R0) 
Isogai et al., unpublished; 
Isogai and Otsuki, unpublished 
- 
COX6C (100.8-100.9) 
(BC000187, P09669) 
Strausberg et al., 2002 - 
POLR2K (101.1) 
(BC018157, P53803) 
Strausberg et al., 2002 - 
HSPG1 (97.5-97.6) 
(J04621, AAA52701) 
 
Marynen et al., 1989 
 
[c.91G>C; p.Ala31Pro];[c.242C>T; p.Thr81Ile]; 
[c.391G>A; p.Ala131Thr];[c.413G>C; p.Arg138Pro]; 
[c.416G>A; p.Arg139Lys];[c.419G>A; p.Arg140Lys]; 
[c.426G>A; p.Lys142Lys];[c.463C>G; p.Leu155Val]; 
[c.799A>T; p.Thr267Ser];[c.763G>A; p.Ala255Thr] 
KCNS2 (99.4) 
(AB032970, Q9ULS6) 
Hirosawa et al., 1999; 
Strausberg et al., 2002 
- 
MATN2 (98.8-99.0) 
(BC010444, Q96FT5) 
Deak et al., 1997; Strausberg et al., 
2002 
[c.560C>T, p.Thr187Met];[c.816G>T, p.Ser272Ser] 
OAZIN-1 (103.8) 
(BC013420, O14977) 
Koguchi et al., 1997; 
Strausberg et al., 2002 
[c.369G>A; p.Ala123Ala] 
PRO1097 (99.4) 
(AF119844, Q9P1A1) 
Zhang et al., unpublished [c.179T>C; p.Val60Ala] 
FLJ13955 (99.2-99.3) 
(AK024017, Q9H841) 
Ota et al., 2004; 
Isogai and Otshuki, unpublished 
[c. 924T>G; p.Thr308Thr] 
FLJ36587 (101.5-101.6) 
(AK093906, Q8N9S9) 
Ota et al., 2004; 
Suzugi et al., unpublished; 
Isogai and Yamamoto, unpublished 
[c.745G>T, p. Ala249Ser] 
Putative gene 1 (101.5) 
(U79297) 
Andersson et al., 1996; Yu et al., 
1997; Yu and Gibbs, unpublished 
- 
 
*
1
 UCSC Genome Browser July 2003 Assembly (http://genome.ucsc.edu/) 
Unpublished references are cited in GenBank. 
Nonsynonymous substitutions are marked in bold.  
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2. The gene for Cohen syndrome (COH1) 
 
2.1. Identification of the COH1 gene (II) 
We did not observe COH1-associated mutations in genes residing within the novel COH1 
region for which sequences were publicly available in gene databases (Figure 5). Therefore 
we expanded the search for the disease gene to include murine homologs for human genes 
by performing blastx searches with the human genomic sequence from the COH1 region. 
By this method a partial mouse protein BAB26477 (Genbank accession number AK009750) 
was identified. By comparing this sequence to human genomic sequences using the tblastn 
program, it was possible for us to predict intron-exon boundaries for the corresponding 
human gene. The exon sequences defined by the similarity search were used to design 
primers for two RT-PCR reactions in two Finnish Cohen syndrome patients. One of the two 
RT-PCR products from these patients showed a two-base pair deletion when sequenced. 
This mutation predicted a frameshift in the human homolog and was subsequently found to 
be present in all Cohen syndrome chromosomes bearing the founder haplotype, thus 
suggesting that this partial transcript sequence belonged to COH1. Further analysis revealed 
several Cohen syndrome-associated mutations in the newly assembled gene (Table 6). The 
full-length COH1 transcript sequence was compiled from 18 ESTs, some of them 
overlapping, one large KIAA0532 cDNA sequence, and COH1-associated in silico-
predicted exons (Figure 6A). The partial transcripts found by BLAST searches and 
predicted exons were linked by RT-PCR. The COH1 transcript of 14,092 nucleotides was 
found to span an 864 kb genomic region, comprising 62 exons in full-length form (Figure 
6B). The transcription start site resides in the second exon and the full-length transcript 
predicts a 4,022 amino acid protein. The COH1 transcript is predicted to have, based on 
ESTs and RT-PCR, at least eight alternative isoforms, three in-frame and five out-of-frame 
(II, Figure 3, IV). Of six alternatively spliced exons, two (exons 28 and 28b) were present 
either separately or together in COH1 transcripts. When they occur separately they result in 
transcripts with substitution alternative splicing, and when occurring together they 
introduce length difference alternative splicing. The remaining four alternatively spliced 
exons resulted in transcripts with length difference alternative splicing. Velayos-Baeza et 
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al. (2004) suggested the occurrence of tandem duplication in the evolution of exons 28 and 
28b (II, Figure 3), spliced by substitution alternative splicing. 
 
2.2. COH1 gene expression (II) 
Multiple-tissue Northern (MTN) blots showed a wide expression pattern for COH1 in 
human MTNI, MTNII, and fetal MTN blots (II, Figure 4) with two RT-PCR amplified 
probes. Three transcripts of ~2, ~5, and ~12-14 kb for COH1 were observed. Of these, the 
largest showed significantly stronger signal in prostate, testis, ovary and colon than in other 
tissues. Interestingly, the brain expression was very low in a blot with adult tissues, while 
the fetal blot showed equally strong signal for all four tissues (brain, lung, liver, kidney) 
studied. Controversially, this pattern was not observed with a probe amplified from a 
cloned cDNA fragment (Velayos-Baeza et al., 2004). This discrepancy was suggested to be 
a result of nonspecific hybridization with RT-PCR amplified probes in the presence of 
highly represented RNAs as a similar pattern of bands was also observed with three other 
human Vps13 homologs by RT-PCR. Velayos-Baeza et al. (2004) showed wide expression 
of different COH1 isoforms, with the brain showing the strongest signal for the full-length 
isoform (AY223814). This is not strongly expressed in other tissues, in which splice variant 
1 (AY223815) is the main form. By RNA in situ hybridization, Mochida et al. (2004) 
showed wide expression of COH1 in postnatal and adult mouse brain but lower expression 
in embryonic mouse brain, which is in contrast to our results in human MTN blots. 
Additionally, they showed wide expression of COH1 in neurons of the central nervous 
system (CNS) while expression was absent in white matter glial cells (Mochida et al., 
2004). Clearly more work is required in order to understand the transcription and 
developmental expression of COH1. 
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Figure 6. A) Complete COH1 transcript sequence built by linking together partial transcripts residing within the COH1 region and 
using in silico-based exon prediction algorithms. Alternative sequence is marked in different colors. Black indicates non-homologous 
regions in comparison to human sequence. B) Genomic structure of the Cohen syndrome gene COH1 spanning an 864 kb region on 
chromosome 8q22.3. Five alternatively spliced exons are boxed and marked in transparent colors corresponding to those in Figure 6A. 
The relative length of exons and introns are to scale, but the introns are not to scale with exons. 
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3. COH1 gene mutations  
 
3.1. Overall characteristics of the COH1 gene mutations (II, III, IV)  
During this study 111 patients with a provisional clinical diagnosis of Cohen syndrome 
were analyzed for mutations in COH1. These patients were divided into three groups based 
on eight clinical criteria (Table 5). Seventy-two of the patients belonged to a “ true”  Cohen 
syndrome group fulfilling six or more previously established diagnostic criteria. Twenty-
three patients belonged to Cohen-like group fulfilling less than six criteria. A third group of 
patients with incomplete clinical data consisted of 16 patients.  
“ True”  Cohen syndrome patients were screened for mutations by sequencing except 
for 27 Finnish patients homozygous for the founder haplotype, who were analyzed by 
single-stranded conformational polymorphism (SSCP) after the founder mutation was 
observed in the cDNA of one of them by sequencing. The Cohen-like patients were 
analyzed by SSCP. Eight patients in the group of incomplete data were sequenced and the 
rest were studied by SSCP. 
To date we have identified 32 different mutations (Table 6 and 7, Figure 7). Six are 
nonsense changes creating stop codons. Fifteen are small deletions and insertions leading to 
frameshifts and predicting early protein truncation. Four of the mutations are splice site 
changes. Of these, two affect splicing of COH1 cDNA, predicting early protein truncation, 
while two have not been verified at the cDNA level. Two of the mutations are missense 
changes. Of the four large exonic deletions two are in-frame changes and two lead to 
predicted early protein truncation. In addition, two nucleotide changes, a one base pair 
insertion causing a frameshift and a missense change, were observed in the same allele 
inherited from both parents in an Amish patient and were shown to segregate in affected 
family members. 
The distribution of mutations over the COH1 gene (Figure 7) demonstrates that 
gene defects were seen only in exons present in the full-length form, and mutational 
hotspots were not observed. Two of the four splice site mutations were seen at the donor 
and acceptor sites of intron 37. Five of the mutations were seen in exon 34, one of the 
largest exons in the COH1 gene. Specific correlations between the mutation site and 
clinical phenotype were not seen (see Results and Discussion section 3.4.).  
RESULTS AND DISCUSSION 53
In addition to the mutations described by us, others have published 22 additional 
mutations in COH1 (Mochida et al., 2004; Hennies et al., 2004). Only one of these, a 
nonsense mutation (7051 C>T; R2351X) in a French patient (Mochida et al.,2004) was 
already observed by us. In total, 53 different mutations have been found in COH1 to date, 
of which interestingly only five are missense changes. Most (85%) of the COH1 mutations 
are protein truncating, probably causing non-functional protein or the transcript to be 
subjected to nonsense-mediated mRNA decay (NMD). 
 
Table 5. Eight diagnostic criteria for separation of “ true”  Cohen syndrome patients and 
those with Cohen like-syndrome. 
 
Diagnostic criteria 
Developmental delay 
Microcephaly 
Typical facial dysmorphism 
Obesity and slender extremities 
Overly sociable behavior  
Joint laxity 
Myopia and/or retinal degeneration 
Intermittent neutropenia 
 
Table 6. Thirty-two different mutation types observed in COH1 
 
Mutation type No.* 
Nonsense mutations  6    (11) 
Missense mutations  2      (3) 
Small deletion/insertion/indel/duplication mutations 15    (7) 
Large exonic deletion mutations 4      (0) 
Splice site mutations 4      (1) 
Double mutation (small insertion+missense) 1      (0) 
Total number of different mutations 32  (22) 
 
*Mutations published by others (Hennies et al., 2004; Mochida et al., 2004) are shown in parentheses.  
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Figure 7. Distribution of mutations in the COH1 gene cDNA grouped by mutation type. 
The two changes identified in the same allele in the Amish patient are shown in brackets. 
 
3.2. COH1 gene mutations in Finland (II, IV) 
The Finnish founder mutation is a two nucleotide deletion [c.3348_3349delCT] resulting in 
a frameshift at codon 1117 and a stop codon after 8 codeshifted amino acids 
[p.Cys1117fsX8, Table 7]. This mutation is present in all Finnish patients except one. The 
founder mutation is homozygous in 27 Finnish patients, heterozygous in 12, and is present 
in 85% (66/78) of the affected chromosomes. The proportion is 73% (31/42) if only one 
affected sib per family is taken into account. The geographical distribution of the Finnish 
founder mutation covers a large part of Finland with the exception of Lapland. In addition 
to the founder mutation, we identified five different “ minor”  COH1 mutations (see Table 7) 
in Finnish patients. This relatively high number of minor mutations is not frequently seen 
among the diseases of the Finnish disease heritage, as more than three Finnish minor 
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mutations have been seen only in six other disorders, i.e. AGU (4 minor mutations, founder 
mutation proportion in affected chromosomes 98%), APECED (7, 90%), Batten disease (4, 
90%), cartilage-hair hypoplasia (4, 92%), congenital nephrosis (7, 78%), and retinoschisis 
(6, 70%). The minor mutations in COH1 comprise one missense and one nonsense 
mutation, [c.6578T>G; p. Leu2193Arg], [c.5827C>T; p.Arg1943X], two frameshifts, 
including a small insertion [c.5730_5731insA; p.Ile1913fsX6] and deletion 
[c.10838_10841delCTCT; p.Leu3614fsX36], and one large in-frame deletion [EX20_21del; 
p.Gly942_Thr1027del], which is not determined on the genomic level and results in the 
skipping of two exons in the processed mRNA. Among the minor mutations, only the 
nonsense mutation [c.5827C>T] was found to be homozygous in one patient. This mutation 
was found in a family from a small parish in western Finland. In four Finnish patients, of 
whom two are siblings, only one disease allele was identified despite extensive screening of 
cDNA and/or genomic DNA. For two of these patients the cDNA was not available, and 
therefore gross genomic deletions and mutations in intronic or regulatory regions affecting 
splicing and/or transcript levels may have been missed with PCR-based sequencing of 
small fragments.  
 
3.3. Consanguinity between Cohen syndrome parents (unpublished) 
Consanguinity was verified in six Cohen syndrome sibships. Consanginity was shown in 12 
parents carrying the main mutation [c.3348_3349delCT] (Figure 8, P1-3). In the largest 
pedigree (P2), five parents were descendants of one ancestral couple. As has been observed in 
other disorders of the Finnish disease heritage, the origin of the founder mutation is probably 
in south Savo, from where migration has brought it to eastern and northern parts of Finland.  
The parents of a patient (P4, Figure 8) homozygous for the minor mutation [c.5827C>T] 
were found to be remotely consanguineous. They and almost all of their ancestors were born 
in the same region in western Finland. The mother of another Cohen syndrome patient (P5, 
Figure 8) carried the same rare mutation. Most of the ancestors of this patient were from an 
entirely different region but one great-grandparent couple was born in the same region as 
family P4 (Figure 8). Consanguinity between these two ancestries could not be verified. This 
less common COH1 founder mutation may have been brought to Finland from the west, or it 
has originated in western Finland. Due to the presence of the main founder mutation at a high 
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frequency, less common private mutations can manifest in the phenotype. Minor mutations 
are also probably present in other populations, but they are not seen because the prerequisite 
for phenotype expression, the second common founder mutation, is missing. Remote 
consanguinities between parents as shown here are typical in disorders of the Finnish disease 
heritage (Norio, 2003b) 
 
Figure 8. Pedigrees (P1-P5) showing consanguinities between Cohen syndrome parents. 
The letters A-D in the map of Finland show birth places of the common ancestors of the 
pedigrees. The Cohen syndrome parents not belonging to the consanguinities are omitted. All 
Cohen syndrome parents displayed in pedigrees 1-3 carry the main mutation 
[c.3348_3349delCT], which is homozygous in all patients with the exception of those in 
pedigree 3. The patients in the two branches of  pedigree 3 share the main mutation 
[c.3348_3349delCT], and have their own private mutations (c.5730_5731insA and 
c.EX20_21del). The circled great-grandparents in pedigree 5 share the birth place of the 
common ancestor pair in pedigree 4, the parents shown in these families carry the same less 
common mutation. 
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3.4. Definition of Cohen syndrome (IV) 
Mutation screening of the three groups totalling 111 patients revealed mutations only in 63 
of 72 diagnosed as having Cohen syndrome and in two patients with incomplete data. This 
allowed us to determine the clinical features associated with molecularly defined Cohen 
syndrome. 
In our study set all patients with an observed mutation in COH1 had developmental 
delay (Table 7). Additional clinical features present in almost all patients with few 
exceptions were typical facial dysmorphism, myopia and/or retinal degeneration, and 
intermittent neutropenia. There was more variation between patients regarding the other 
four diagnostic criteria, and our results suggest that these are supportive, but not crucial for 
Cohen syndrome diagnosis. Thus developmental delay, typical facial dysmorphism, myopia 
and/or retinal degeneration and intermittent neutropenia can be considered essential 
features of Cohen syndrome. 
Of the four diagnostic criteria important in Cohen syndrome facial features were 
typical in all patients except the Amish patients who had synophrys, not commonly seen in 
Cohen syndrome. However, other typical features were present in these patients including 
thick hair and long eyelashes, wave-shaped palpebral fissures, low nasal bridge, short 
philtrum and open mouth appearance. There is probably variation in Cohen syndrome facial 
characteristics due to the ethnic origin of the patients, as has been shown in other studies 
(Horn et al. 2000). Ophthalmological changes were present in all but three patients, of 
whom one was under five years of age at the time of the study, and two patients for whom 
data on ophthalmic changes or clinical confirmation of the ophthalmic changes was 
missing. Intermittent neutropenia was not reported in one patient and two patients had no 
data for the neutrophil count. 
To date, COH1 mutation analysis with patients having diagnosed Cohen syndrome 
and medical reports available has been performed in two studies in addition to ours. 
Mochida et al. (2004) reported patients of four families with COH1 mutations with more 
phenotypic variability than the Cohen syndrome patients we presented. Granulocytopenia 
was not observed in patients from two families and was not assessed in one. However, 
blood counts were tested only once, which leaves open the possibility of an incorrect 
interpretation due to the intermittent nature of granulocytopenia (Kivitie-Kallio et al., 
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1997). Ophthalmological studies were missing in two pedigrees, but in two families myopia 
and either retinal dystrophy or retinitis pigmentosa was reported (Mochida et al., 2004). 
Hennies et al. (2004) disputed the clinical criteria for Cohen syndrome presented in our 
study for cohorts having diverse origins, and postulated this to be due to allelic 
heterogeneity in Cohen syndrome. The only features present in all patients with mutations 
in COH1 were developmental delay, early-onset myopia, joint laxity, and facial 
dysmorphism (Hennies et al., 2004). Their patients lacking retinopathy were young and 
mostly under five years of age, while retinal changes usually develop at a later age, but all 
of them had myopia. Granulocytopenia was only observed in about half of their patients 
despite repeated testing, which might indicate variability in Cohen syndrome concerning 
this feature. 
 
Table 7. Clinical features used in study IV to differentiate “ classical”  Cohen syndrome 
patients from Cohen syndrome-like patients. The clinical phenotypes of 65 Cohen 
syndrome patients with 32 different mutations are shown.  
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F1 / Finland [p.Cys1117fsX8]+[p.Arg1943X] EX23, EX34 + + + + + + + + 
F2 / Finland [p.Arg1943X]+[p.Arg1943X] EX34, EX34 + + + + + + + + 
F3 / Finland [p.Cys1117fsX8]+[p.Ile1913fsX6] EX23, EX34 + + + + + + + + 
F4 / Finland [p.Cys1117fsX8]+[p.Leu3614fsX36] EX23, EX56 + + + - - + + + 
F5 / Finland [p.Cys1117fsX8]+[p.Gly942_Thr1027del] EX23, EX20, EX21 + + + + + + + + 
F6 / Finland [p.Cys1117fsX8]+[p.Gly942_Thr1027del] EX23, EX20, EX21 + + + + + + + + 
F7 / Finland [p.Cys1117fsX8]+[p.Leu3614fsX36] EX23, EX56 + + + - - + + + 
F8 / Finland [p.Cys1117fsX8]+[p.?] EX23, ? + + + + + + + + 
F9 / Finland [p.Cys1117fsX8]+[p.?] EX23, ? + + + + + + + + 
F10 / Finland [p.Cys1117fsX8]+[p.?] EX23, ? + + + - + + + a 
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F11 / Finland [p.Cys1117fsX8]+[p.?] EX23, ? + + + - + + + a 
F12 / Finland [p.Cys1117fsX8]+[Leu2193Arg] EX23, EX37 + + + - + + + + 
F13 / Finland [p.Cys1117fsX8]+[Leu2193Arg] EX23, EX37 + + + - + + + + 
F14-40 / Finland [p.Cys1117fsX8]+[p.Cys1117fsX8] EX23, EX23 + + + b + + c + 
UK1 / United Kingdom [p.Ser3970fsX22]+[p.?] EX61, ? + + + - - + + + 
UK2 / United Kingdom [p.Gln1445fsX7]+[p.?] EX29, ? + + + - + + + + 
UK3 / United Kingdom [p.Val3340fsX9]+[p.?] EX55, ? + - + - + + + + 
UK4 / United Kingdom [p.Leu2674_Gln2725del]+[p.?] EX44, ? + + + - + + + + 
UK5 / United Kingdom [p.Asn156fsX4]+[p.Asn156fsX4] EX4, EX4 + + + + + + + + 
UK6 / United Kingdom [p.Glu2900fsX2]+[p.Glu2900fsX2] IVS46, IVS46 + - + + + + + + 
UK7 / United Kingdom [p.Glu2900fsX2]+[p.Glu2900fsX2] IVS46, IVS46 + + + + - + + + 
UK8 / United Kingdom [p.Trp2824X]+[p.?] EX46, ? + + + + - + + - 
UK9 / United Kingdom [p.Trp963X]+[p.?] EX19, ? + + + + + - + + 
UK10 / United Kingdom [Glu1491X]+[Glu1491X] EX28, EX28 + + + + - + d + 
UK11 / United Kingdom [Glu1491X]+[Glu1491X] EX28, EX28 + + + + - + + + 
UK12 / United Kingdom [Glu1525fs44X]+[Ala1570fs3X] EX28, EX28 + + + + + - + + 
NL1 / Holland [p.Ser1917fsX19]+[p.Arg3230fsX20] EX33, IVS52 + + + + + + + + 
NL2 / Holland [p.Ser1873fsX9]+[p.Arg3725fsX7] EX33, EX57 + + + + + + + + 
D1 / Denmark [p.Gln2140fsX27]+[p.Leu2781X] EX36, EX45 + + + + + - + + 
D2 / Denmark [p.Pro8fsX3]+[p.?] EX2, ? + + + + + - + + 
B1 / Belgium [p.Asn2993Ser]+[p.Asn2993Ser] EX49, EX49 + + + + + + + + 
B2 / Belgium [p.Asn2993Ser]+[p.Asn2993Ser] EX49, EX49 + + + + + + + + 
B3 / Belgium [p.Arg692X]+[p.Trp1810fs20X] EX15, EX34 + + + + + + + + 
B4 / Belgium [p.Arg692X]+[ p.Trp1810fs20X] EX15, EX34 + + + + + + + + 
B5 / Belgium [p.Arg2351X]+ [p.Arg2351X] EX39, EX39 + + + + + + + + 
B6 / Belgium [p.Arg2351X]+ [p.Arg2351X] EX39, EX39 + + + + + + + + 
US1 / U.S.A. [p.Leu3087fsX20+p.Ile2820Trp]+ 
[p. Leu3087fsX20+p.Ile2820Trp] EX51, EX51 + + - + + + + + 
US2 / U.S.A. [r.spl?;p.?]+[p.?] IVS38, ? + + + a + a + a 
I1 / Israel [p.Pro3969fsX41]+[r.spl?;p.?] EX62, IVS38 + + + + + a a a 
 
a) no data available 
b) present in 17% of patients 
c) retinal degeneration present in all but one patient under five years of age 
d) no data 
* prefix EX denotes exon and IVS intron 
Double line frames and gray background color indicate the siblings. 
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4. Predicted characteristics of the COH1 protein (II and unpublished) 
 
4.1. Complex structure of the COH1 protein 
The hydrophobic and alpha helical amino acid sequence regions in COH1 indicate the 
protein has 10 transmembrane (TM) domains. This was supported by data from the Gene 
Ontology Annotation (GOA) database (Camon et al., 2004) available from Entrez Gene at 
NCBI. Similarity searches in the protein domain family database ProDom (Gouzy et al., 
1999) revealed that the COH1 N- and C-terminal sequences are homologous to S. 
cerevisiae vacuolar protein sorting protein 13 (Vps13). In addition, the COH1 protein has a 
complex pattern of predicted functional motifs with signals for both endoplasmic reticulum 
(ER) retention (Teasdale and Jackson, 1996; aa 4018-4021) and peroxisomal targeting 
(McNew and Goodman, 1996; aa 263-271 and aa 3553-3561). Amino acid segments for a 
leucine zipper pattern (Landschulz et al., 1989; aa 30-51) and zinc metallopeptidase 
(Jongeneel et al., 1989; aa 3289-3298) were also detected. The participation of COH1 in 
vacuolar-targeted sorting of protein transfer was further supported when a possible vacuolar 
targeting motif (Stack et al., 1995) was found at amino acid positions 1518-1521.  
The gene structure of COH1 is similar to another human disease-causing gene, 
CHAC (Rampoldi et al., 2001; Ueno et al., 2001). The defect in CHAC leads to 
Choreoacanthosytosis (Critchley et al., 1968), a disorder with neuronal and haematopoietic 
involvement. The encoded chorein protein has moderate overall sequence homology to the 
COH1 protein. COH1 and chorein probably belong to a novel family of Vps13-like human 
proteins. The COH1, chorein and S. cerevisiae Vps13 all have conserved N- and C-terminal 
domain structure (II; Rampoldi et al., 2001; Ueno et al., 2001). Both COH1 and CHAC 
encode large proteins, 4,022 and 3,174-amino acids respectively, and have on average small 
exons (62 and 72 exons). Both genes span a large genomic region (864 kb and 220 kb), 
which is four times larger for COH1 (II; Rampoldi et al., 2001; Ueno et al., 2001). 
 
4.2. ER retention signal in COH1 protein 
The COH1 protein possesses a carboxy-terminal dibasic motif, a KKXX-like motif RKGF 
at the -5 position, in which one of the lysine residues is substituted with arginine. In this 
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motif a lysine or arginine residue is positioned at -3, -4, or -5 from the C-terminus, and the -
4 lysine could be moved to the -5 position without losing function (Jackson et al., 1990, 
Shin et al., 1991). Although a conserved di-lysine motif is present in many ER proteins, 
some substitutions of lysine by arginine are permitted (Teasdale and Jackson, 1996). This 
dibasic motif is a typical signal for membrane proteins mediating sorting between the ER 
and the Golgi apparatus (Teasdale and Jackson, 1996). Di-lysine motifs bind complexes of 
cytosolic coat protein, COP1, and work in a secretory pathway to retrieve proteins from the 
Golgi to the ER (Teasdale and Jackson, 1996). The importance of the ER retention signal in 
Cohen syndrome and possible functional divergence of the COH1 protein is unclear. 
However, proteins interacting with the adaptor protein 3 (AP3) tetramer complex during 
protein sorting have ER retention function in addition to endosomal/lysosomal targeting. 
The cargo protein, neutrophil elastase, for the AP3 complex has an amino-terminus ER 
retention signal (XXRR), and one of the AP3 complex subunits, AP3B1, a vacuolar 
targeting motif. The AP3 complex is known to be involved in routing of proteins between 
trans-Golgi and lysosomes (Obermüller et al., 2002). Interestingly, a mutation in AP3B1 
encoding the b subunit of AP3, dissociates the tetramer leading to mislocalization of the 
cargo protein. Mutations in both the ELA2 and AP3B1 genes cause cyclic neutropenia in 
dogs (Ozsoylu, 2001; Dell’ Angelica et al., 1998), and mutation of the AP3B1 gene is 
causative in human Hermansky Pudlak syndrome type 2 (HPS2), which also involves 
retinal hypopigmentation. It has been suggested that mistargeting of neutrophil elastase, 
encoded by ELA2, also causes intermittent neutropenia in Cohen syndrome (Horwitz et al., 
2004). 
 
4.3. Rodent COH1 orthologs 
The predicted mouse homolog for the COH1 protein is comprised of 3,965 amino acids, 
and the partial transcript consists of 11,986 nucleotides. The gene has 62 exons, spanning 
~558 kb has a translation starts from nucleotide 29 in exon two. Mouse Coh1 has 85.5% 
overall mRNA similarity to human COH1. In silico protein analysis shows the signal 
sequences to be conserved in comparison to human COH1 protein, and the hydrophobicity 
profile predicts seven transmembrane domains.  
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The predicted 12,271 nucleotide rat Coh1 spanning ~624 kb has a translation start 
site in exon two, 62 exons, and encodes a 3,995 amino acid protein. It has functional 
domains similar to the human ortholog. Exceptionally, the rat protein has a third 
peroxisomal targeting signal 2 (PTS2) signature domain at amino acid 2,465 and eight 
predicted transmembrane domains. Additionally, the first untranslated exon in mouse and 
rat included in ESTs BB596466 and CB691391, respectively, differs from the human 
COH1 transcript. The similarity of the mouse and rat COH1 proteins to human COH1 
protein isoform 1 is 87.5% and 86.7% respectively. 
 
4.4. COH1 promoter region (unpublished) 
The CpGProD program (Ponger and Mouchiroud, 2001), designed to predict promoters 
associated with CpG islands, was used in the prediction of a potential transcription 
regulating region 5´-upstream of the COH1 coding sequence. In humans a GC-rich 
promoter region was observed 1,310 nucleotides upstream (and 185 nucleotides 
downstream from the COH1 transcription start codon), continuing 1,498 nucleotides 
downstream. The strength of prediction was moderate with a start-p value of 0.31. It is 
known that 50%-60% of human genes display a CpG island over the transcription start 
codon (Ponger and Mouchiroud, 2001). In the corresponding mouse and rat genome 
sequences, good start-p values of 0.57 and 0.53 for the GC-rich promoter region was 
predicted starting 1162 and 1179 nucleotides upstream from the putative COH1 
transcription starting codon.  
Three conserved putative transcription factor (TF) binding sites (ELK1, ETS1P54, 
and NRF2) in human, mouse and rat were observed with the MATCH program 
(http://www.gene-regulation.com/pub/programs.html#match). These overlap in the 
genomic region upstream of the COH1 transcription start codon (Figure 9). ELK1 (Rao et 
al., 1989) belongs to the ETS gene family (Watson et al., 1988), of which the ETS1 family 
comprises proteins encoding nuclear phosphoproteins (Li et al., 2000). The ETS proteins 
are transcription factors that interact with purine rich promoter/enhancer region sequences 
of genes (Karim et al., 1990). Characteristically, proteins that have an ETS transcription 
factor do not possess typical transcription regulating “ TATA”  or “ GAAT”  elements 
(Mavrothalassitis et al., 1990; Jorcyk et al., 1991), which holds true also for the COH1 gene 
RESULTS AND DISCUSSION 63
promoter region. In general, ETS proteins are associated with processes of cell growth 
control, embryological development and hematopoietic differentiation (Hromas and 
Klemsz, 1994; Seth et al., 1992; Crepieux et al., 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Predicted COH1 promoter region and conserved transcription factor binding sites 
(boxed in blue) within the COH1 5´-upstream regulatory region in human, mouse and rat. 
The first non-coding exon is boxed in red. 
 
 human(Hs.)-567 GGGACAGTTTGTTTTGAGCACCAAGTGGGACACACCCGGAAGTGGCGCGGTACAGGAGCA -508
mouse(Mm.)-479 CGGACGG-------------CGAAGCCCG-CACACCCGGAAGTGGCGCGGAACGCGTGAG -434
rat (Rn.) -487 GGGACTG-------------CAAAGCGGG-CACACC-GGAAGTGTCGCGGAACGCGGCCG –442
human(Hs.)-507 GCACTGCCGGCGGGGGCGGGTGCCAGGGACTTGGAGGTGGAGGGGACGCGGCGGTACTCT –448
mouse(Mm.)-433 GCGTTTCCGC----GGCGGACGCCAGGTACCCGGAGGAAGAGCGCACGCCGCCGCTCTGT –378
rat (Rn.) –441 GCGCGTCCGC----GGCGGACTCCAGGTACCCGGAGGAGGAGCGCACGCCGCCACTCTGT –386
human(Hs.)-447 GGCGTGTGAGCCGAGGGTGGAGTGCAGAGGGAGCGGGAGCGGGACGGGAGGTCTTCTAGC –388
mouse(Mm.)-377 GGCGTGTTTACCTTGGAGCGGGTGCGGCGGCGGCGGCAGCAG--CGGGCCTGACGCCAGC –320
rat (Rn.) –385 GGCGTGTTTACCTTGGAGCGGGTGCGGCGGCGGC---AGCAG--CGGGCCTGACGCCAGC –331
human(Hs.)-387 TTTGGTTCTATGGTGGCAGATCCGGCTGGGTTCCGGGAAGCGAGGGCCTCGCGGGGTGGC –328
mouse(Mm.)-319 TCGG-TCCTATGGCCGGAGATCCGCCTGCGTTCCGGGAGTCGACCGCCTC------TGGC -267 
rat (Rn.) –330 TCGGGTTCTATGGCCGGAGATCCGCCTGCGTTCCGGGAGTCGACCGCCTC------AGGC –277
human(Hs.)-327 TGGGTTGGTGAAGGGCTACTGCGGCCGAAGGGGAGCCCGCCTCACTTCATTCTTCCACTC –268
mouse(Mm.)-266 TGGGCTGCGCTAGGGTAG----GAGTGAAGCAGGACGTGCT-------GTCCTCCCACGC –228
rat (Rn.) –276 TGGGCTGCGCTAGGGCCA----GAGTGAAGGGGGCCGCGCT-------CTCCTCCCACGT –238
human(Hs.)-267 TGAGGGACCCGCTCTCTTCTGGTCACTACGTCTTCCTCCCTCACTTCGCTTGGCGAAGGG –208
mouse(Mm.)-227 CCGGGGGCCGGC-CGCCTCCAGCCTCTCTGCCTACT-------CCTCGTCAGGTGAGGCG –176
rat (Rn.) –237 CCGGGGACCGGC-CGCCTCCAGCCTCTTTGCCTACT-------CTTGGTCAGGTGAGGCG –186
human(Hs.)-207 TGTTGTACTTGTGAGGAAGTCGCAGCTGGAGCTGGGAGTCCGCT--GGAGTTTTTCTCTG –150
mouse(Mm.)-175 CTCAGT--TAGCGGGGAGCTCGCGCCCGGACCCGGAGGGCGGGC---GGGCGATCCGGGA –121
rat (Rn.) –185 CACAGT--TAGCGGGGAGGTCGCGGCCGGACAGGGAAGGTGTTCTTGGAGAAACCTGCGG –128
human(Hs.)-149 TTTCTAAGAGGAGGCGAACGGCCGCTTTGGTGGGGACTTACTGCTTTCGGCCTGAGATAA  –90
mouse(Mm.)-120 GAGC-----GGCCTTGCCAAGCTTCCTGAGAAGTGCATTTCCAGTTGCTGCCTGT----- -71
rat (Rn.) –127 CCGCCTGTTGGCCTCGCCAGGCTTCCCGAGAAGTGTTTTTCCAGTCGTTGCCTGC----- -73
human(Hs.)-89  CGAACGCTCTTTCCTTCACTCTACCGCCGACTTCTAACGTTTCTGTCTACTCCTTTCAG   -30
mouse(Mm.)-70  CGA---TTCAGTTACTTACAAAATTTCCGTCTTTACCCTTTT-CAG------------- -29
rat (Rn.) –72  CGA---TTCAGTTACTTACAAAATTTCCGTCTTTACCCTTTTTCAG------------- -30
                                                                                               RESULTS AND DISCUSSION 64
5. COH1 function in respect of diseases involving trans-Golgi protein sorting  
The role of COH1 in cellular events can only be hypothesized since experimental evidence 
for the protein function is not available. Interestingly, we observed homology of COH1 to 
S. cerevisiae Vps13. Vps proteins have several functions in secretory pathway protein 
sorting and vacuolar biogenesis in eukaryotes. The yeast vacuole and mammalian lysosome 
share many features and are thus believed to be functionally equivalent compartments, and 
derived from a branch of the secretory pathway. Vps proteins participate in several steps in 
the retrieval of proteins from the post-Golgi compartment. Vps-associated proteins in yeast 
are known to have a receptor function, and are involved in segregation and packaging of 
proteins into vesicular carriers. Vps proteins participate in vesicle formation and membrane 
fusion, are vesicle coat proteins, take part in targeting and recognition of the carriers, 
recycle receptors, and have a role in maintenance of vacuolar structure (Stack et al., 1995). 
Since COH1 has sequence homology to yeast Vps13 protein, we can assume the 
involvement of these proteins in similar processes in the cell. Four human proteins (COH1, 
chorein, VPS13C, and VPS13D) have been characterized to date that have N- and C-
terminal homology to Vps13, and all except COH1 also have a third homologous region 
and a repeated 45 amino acid core element (Velayos-Baeza et al., 2004). These proteins 
form a new Vps13-like protein family (Ramboldi et al., 2001; Ueno et al., 2001; Velayos-
Baeza et al., 2004). Of these proteins, COH1 and chorein, underlying choreoacanthocytosis, 
are known to be disease-causing if defective. Choreoacanthocytosis is characterized by 
progressive neurodegeneration and red cell acanthocytosis (Rubio et al., 1997). 
Interestingly, the disease phenotype in both Cohen syndrome and choreoacanthocytosis 
includes hematological aberration and neurologic abnormality. 
COH1 predicted function as well as Cohen syndrome clinical features share some 
similarity to other diseases involved in protein sorting from the trans-Golgi network, in 
particular hypopigmentation disorders which also involve retinitis pigmentosa and 
neutropenia, essential features in Cohen syndrome. Many of the proteins underlying 
hypopigmentation disorders are known to participate in protein sorting between the trans-
Golgi and lysosomes. Interestingly, there is growing evidence of the involvement of 
intracellular protein sorting and trafficking in disorders of the CNS. For example, disorders 
associated with congenital microcephaly and mental retardation are caused by mis-targeting 
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in apical sorting of proteins in neuronal progenitor cells (Sheen et al, 2004; Bond et al., 
2003). However, the pathomechanism for aberrant brain development in these is probably 
different than that in Cohen syndrome, as based on the RNA in situ expression profile, the 
COH1 protein functions primarily in postmitotic cells and not in neuronal progenitor cells 
(Mochida et al., 2004).  
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
The clinical definition of Cohen syndrome and its diagnostic criteria has been disputed 
within the scientific community. Our results indicated Cohen syndrome to be a clinical 
entity, and excluded most features of what has been thought to represent phenotype 
heterogeneity. The results also emphasized the importance of careful ophthalmologic 
studies and repeated determination of the leukocyte count before diagnosing Cohen 
syndrome. The study also confirmed the age-dependency of retinal changes and the 
possibility of ethnic variation in facial features in Cohen syndrome. The observations 
described here will facilitate the diagnosis of Cohen syndrome and are of use in genetic 
counseling.  
 A wide variety of mutations were found in the COH1 gene. Most of the mutations 
are protein truncating and the spectrum of mutations covers the whole gene. Due to the 
number of mutations and the large size of the gene, implementing a comprehensive 
diagnostic test is in practice impossible. However, the high proportion of affected 
chromosomes carrying a founder mutation in Finland provides a possibility for a diagnostic 
gene test. Diagnosis by minisequencing is indeed already available for this mutation. The 
currently available test is appropriate mainly for Finnish Cohen syndrome patients, since a 
world-wide founder origin has not been observed. The majority of observed mutations in 
COH1 predict protein truncation with possible degradation already at the mRNA level, 
which might allow diagnostic approaches based on indications of reduced mRNA/protein 
levels. 
Homology searches with the predicted COH1 protein sequence revealed that the 
COH1 gene encodes a novel protein belonging to the group of vacuolar protein sorting-
associated proteins. The significance of several other predicted functional domains needs 
experimental proof. Future studies of the COH1 protein might be based on the hypothesis 
that it has a function in vacuolar protein sorting. 
Various steps in protein trafficking between the trans-Golgi network and lysosomes 
are affected in a group of hypopigmentation disorders. The involvement of a retinal defect 
as well as failure of granulocyte development connect these disorders and prompt the 
suggestion that a defect in COH1 affects granule structure-containing cell types. The 
CONCLUDING REMARKS AND FUTURE PROSPECTS 67
question of whether the protein-sorting machinery is also affected in Cohen syndrome 
should be unraveled in future protein studies.  
The basic issues for future studies are the delineation of COH1 alternative mRNAs 
and experimental clarification of the COH1 protein structure. Important objectives for 
future studies are also the determination of COH1 expression regulation mechanisms, 
description of COH1 protein interactions, clarification of the subcellular localization of the 
COH1 protein, and determination of its involvement in developmental patterns. Putting this 
together, the clarification of COH1 protein function will help us to understand this disorder 
better, and might open alternatives for treatment. The study presented here serves as a basis 
for future research. 
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